Search Result

Results for "

prostate

" in MCE Product Catalog:

By Targets:	5 alpha Reductase (6) Acyltransferase (1) ADC Cytotoxin (5) ADC Linker (3) Adenosine Receptor (1) Adenylate Cyclase (1) Adrenergic Receptor (26) Akt (6) Aldehyde Dehydrogenase (ALDH) (5) Amino Acid Derivatives (1) AMPK (3) Androgen Receptor (62) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (3) Apoptosis (81) Aryl Hydrocarbon Receptor (1) ATM/ATR (1) Autophagy (14) Bacterial (6) Bcl-2 Family (2) Bcr-Abl (3) Biochemical Assay Reagents (1) c-Fms (1) c-Kit (1) c-Met/HGFR (1) c-Myc (3) Cannabinoid Receptor (1) Carboxypeptidase (1) Caspase (6) Cathepsin (2) CCR (1) CD3 (2) CDK (3) Ceramidase (1) Chloride Channel (1) CTLA-4 (1) CXCR (2) Cytochrome P450 (3) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Drug Metabolite (5) Drug-Linker Conjugates for ADC (3) E1/E2/E3 Enzyme (1) EGFR (1) Endogenous Metabolite (15) Endothelin Receptor (1) Epigenetic Reader Domain (20) Estrogen Receptor/ERR (3) Fatty Acid Synthase (FASN) (7) Fluorescent Dye (1) Fungal (1) FXR (2) Glucosidase (1) GnRH Receptor (15) HBV (1) HDAC (5) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (1) Histone Acetyltransferase (4) Histone Demethylase (8) Histone Methyltransferase (6) HIV (4) HPV (1) HSP (3) HSV (1) IAP (2) Influenza Virus (2) Integrin (2) IRE1 (1) Isotope-Labeled Compounds (2) Kisspeptin Receptor (3) Ligands for E3 Ligase (4) Ligands for Target Protein for PROTAC (1) Lipoxygenase (3) LPL Receptor (1) MDM-2/p53 (2) Microtubule/Tubulin (8) Mitophagy (1) MMP (1) Monoamine Oxidase (3) mTOR (3) Neurokinin Receptor (1) NF-κB (4) NO Synthase (1) Nuclear Factor of activated T Cells (NFAT) (1) P-glycoprotein (2) p38 MAPK (1) Parasite (2) PARP (7) PD-1/PD-L1 (1) Phosphatase (5) Phosphodiesterase (PDE) (2) Phospholipase (1) PI3K (3) Pim (2) PKC (2) Polo-like Kinase (PLK) (1) Potassium Channel (1) PPAR (2) Progesterone Receptor (5) Prostaglandin Receptor (1) PROTAC Linkers (2) PROTACs (19) Proteasome (1) Pyruvate Kinase (1) Raf (3) Ras (4) Reactive Oxygen Species (6) Reverse Transcriptase (4) ROCK (1) ROR (1) ROS Kinase (1) SARS-CoV (5) Ser/Thr Protease (1) Serotonin Transporter (2) SHP2 (3) Sirtuin (2) Src (3) STAT (3) Survivin (1) Telomerase (4) Topoisomerase (3) TRP Channel (4) VD/VDR (1) VEGFR (3) Virus Protease (1) Wnt (2)
By Research Areas:	Cancer (356) Cardiovascular Disease (13) Endocrinology (52) Infection (18) Inflammation/Immunology (26) Metabolic Disease (17) Neurological Disease (9)

By Targets:

5 alpha Reductase (6)

Acyltransferase (1)

ADC Cytotoxin (5)

ADC Linker (3)

Adenosine Receptor (1)

Adenylate Cyclase (1)

Adrenergic Receptor (26)

Akt (6)

Aldehyde Dehydrogenase (ALDH) (5)

Amino Acid Derivatives (1)

AMPK (3)

Androgen Receptor (62)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (3)

Apoptosis (81)

Aryl Hydrocarbon Receptor (1)

ATM/ATR (1)

Autophagy (14)

Bacterial (6)

Bcl-2 Family (2)

Bcr-Abl (3)

Biochemical Assay Reagents (1)

c-Fms (1)

c-Kit (1)

c-Met/HGFR (1)

c-Myc (3)

Cannabinoid Receptor (1)

Carboxypeptidase (1)

Caspase (6)

Cathepsin (2)

CCR (1)

CD3 (2)

CDK (3)

Ceramidase (1)

Chloride Channel (1)

CTLA-4 (1)

CXCR (2)

Cytochrome P450 (3)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (1)

Drug Metabolite (5)

Drug-Linker Conjugates for ADC (3)

E1/E2/E3 Enzyme (1)

EGFR (1)

Endogenous Metabolite (15)

Endothelin Receptor (1)

Epigenetic Reader Domain (20)

Estrogen Receptor/ERR (3)

Fatty Acid Synthase (FASN) (7)

Fluorescent Dye (1)

Fungal (1)

FXR (2)

Glucosidase (1)

GnRH Receptor (15)

HBV (1)

HDAC (5)

Hedgehog (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histamine Receptor (1)

Histone Acetyltransferase (4)

Histone Demethylase (8)

Histone Methyltransferase (6)

HIV (4)

HPV (1)

HSP (3)

HSV (1)

IAP (2)

Influenza Virus (2)

Integrin (2)

IRE1 (1)

Isotope-Labeled Compounds (2)

Kisspeptin Receptor (3)

Ligands for E3 Ligase (4)

Ligands for Target Protein for PROTAC (1)

Lipoxygenase (3)

LPL Receptor (1)

MDM-2/p53 (2)

Microtubule/Tubulin (8)

Mitophagy (1)

MMP (1)

Monoamine Oxidase (3)

mTOR (3)

Neurokinin Receptor (1)

NF-κB (4)

NO Synthase (1)

Nuclear Factor of activated T Cells (NFAT) (1)

P-glycoprotein (2)

p38 MAPK (1)

Parasite (2)

PARP (7)

PD-1/PD-L1 (1)

Phosphatase (5)

Phosphodiesterase (PDE) (2)

Phospholipase (1)

PI3K (3)

Pim (2)

PKC (2)

Polo-like Kinase (PLK) (1)

Potassium Channel (1)

PPAR (2)

Progesterone Receptor (5)

Prostaglandin Receptor (1)

PROTAC Linkers (2)

PROTACs (19)

Proteasome (1)

Pyruvate Kinase (1)

Raf (3)

Ras (4)

Reactive Oxygen Species (6)

Reverse Transcriptase (4)

ROCK (1)

ROR (1)

ROS Kinase (1)

SARS-CoV (5)

Ser/Thr Protease (1)

Serotonin Transporter (2)

SHP2 (3)

Sirtuin (2)

Src (3)

STAT (3)

Survivin (1)

Telomerase (4)

Topoisomerase (3)

TRP Channel (4)

VD/VDR (1)

VEGFR (3)

Virus Protease (1)

Wnt (2)

By Research Areas:

Cancer (356)

Cardiovascular Disease (13)

Endocrinology (52)

Infection (18)

Inflammation/Immunology (26)

Metabolic Disease (17)

Neurological Disease (9)

382

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas

HY-118091A

Bexlosteride LY300502	Others	Cancer
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer.

HY-P2450

Leucinostatin A Antibiotic P168	Fungal Antibiotic	Cancer Infection
Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies.

HY-N8850

Angelol G	Others	Cancer
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH).

HY-130574

MnTE-2-PyP chloride BMX-010 chloride	Reactive Oxygen Species	Cancer
MnTE-2-PyP (BMX-010) chloride is a ROS scavenger and potent radioprotector. MnTE-2-PyP also is a manganese porphyrin, protects normal prostate tissue from radiation damage. MnTE-2-PyP can be used for the research of diabetic prostate cancer.

HY-N10491

Spongionellol A	P-glycoprotein	Cancer
Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer.

HY-14249

Bicalutamide	Androgen Receptor Autophagy	Cancer
Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer.

HY-B0192A

Alfuzosin hydrochloride SL 77499-10	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH).

HY-B0192

Alfuzosin SL 77499	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH).

HY-125399

PSMA-11 HBED-CC-PSMA	Others	Cancer
PSMA-11 is a positron emission tomography (PET) tracer. PSMA-11 detects prostate cancer relapses and metastases by binding to the extracellular domain of prostate-specific membrane antigen (PSMA).

HY-136383

AZA1 Rac1/Cdc42-IN-1	Ras Apoptosis	Cancer
AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion.

HY-W013272

Hydroxyflutamide HFT	Androgen Receptor	Cancer
Hydroxyflutamide (HF), an active metabolite of Flutamide, is a potent androgen receptor antagonist (IC₅₀=700 nM). Hydroxyflutamide can be used for the research of prostate cancer.

HY-N7924

Astragenol	Others	Cancer Inflammation/Immunology
Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research.

HY-110154

NSC636819	Histone Demethylase	Cancer
NSC636819 is a competitive and selective inhibitor of KDM4A/KDM4B. KDM4A/KDM4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer.

HY-70002

Enzalutamide MDV3100	Androgen Receptor Autophagy	Cancer
Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator.

HY-P99188

Carlumab CNTO 888	CCR	Cancer
Carlumab (CNTO 888) is a humanised anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer.

HY-138641

Bavdegalutamide ARV-110	Androgen Receptor	Cancer
Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer.

HY-N10492

Spongionellol A analog 1	P-glycoprotein	Cancer
Spongionellol A analog 1, an analog of Spongionellol A (HY-10491), is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A analog 1 has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A analog 1 can be used in the research of cancers, such as prostate cancer.

HY-P0013

Antide
D-21074; ORF 23541
GnRH Receptor Cancer

Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.

Antide D-21074; ORF 23541	GnRH Receptor	Cancer
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Cancer Endocrinology
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer.

HY-P3501

Fexapotide NX-1207 free acid	Apoptosis	Cancer
Fexapotide (NX-1207 free acid) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research.

HY-124292

Honokiol DCA Honokiol dichloroacetate	Androgen Receptor	Cancer
Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level.

HY-70002S1

Enzalutamide-d6 MDV3100-d₆	Androgen Receptor	Cancer
Enzalutamide-d₆ is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1].

HY-16168A

Degarelix	GnRH Receptor Apoptosis	Cancer Endocrinology
Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix can be used for prostate cancer research.

HY-16168B

Degarelix acetate hydrate	GnRH Receptor Apoptosis	Cancer Endocrinology
Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research.

HY-78884

Anticancer agent 9	Amino Acid Derivatives	Cancer
Anticancer agent 9, a glycine derivative, is an anticancer agent. Anticancer agent 9 can inhibit tumor cells viability of myelogenous leukemia and human prostate cancer.

HY-B0391A

Naftopidil dihydrochloride KT-611 dihydrochloride; BM-15275 dihydrochloride	Adrenergic Receptor	Cancer
Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil dihydrochloride has antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia.

HY-B0391B

Naftopidil hydrochloride KT-611 hydrochloride; BM-15275 hydrochloride	Adrenergic Receptor	Cancer
Naftopidil hydrochloride (KT-611 hydrochloride) is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil hydrochloride has antiproliferative effects. Naftopidil hydrochloride can be used for the research of prostate hyperplasia.

HY-B0391

Naftopidil KT-611; BM-15275	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia.

HY-16498

Tigapotide PCK-3145	Apoptosis	Cancer
Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels.

HY-122197

ML339	CXCR	Cancer
ML339 is a potent and selective CXCR6 (IC₅₀ of 140 nM) antagonist that is selective (IC₅₀ >79 μM) against CXCR5, CXCR4, CCR6 and Apelin receptor (APJ). ML339 holds potential to advance the field of prostate cancer research.

HY-145451

Androgen receptor antagonist 2	Androgen Receptor	Cancer Metabolic Disease
Androgen receptor antagonist 2 (example 12) is an androgen receptor antagonist. Androgen receptor antagonist 2 can be used for prostate cancer and male hair loss research.

HY-70002S

Deutenzalutamide Enzalutamide-d₃; MDV3100-d₃	Androgen Receptor Autophagy	Cancer
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.

HY-100199

HUHS015
Others Cancer

HUHS015 is a potent prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitor with an IC₅₀ of 0.67μM for PCA-1.

HUHS015	Others	Cancer
HUHS015 is a potent prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitor with an IC₅₀ of 0.67μM for PCA-1.

HY-32345

Elocalcitol BXL-628; Ro-26-9228	VD/VDR	Cancer Inflammation/Immunology
Elocalcitol (BXL-628) is a selective, orally active vitamin D receptor (VDR) agonist. Elocalcitol shows anti-inflammatory activity. Elocalcitol inhibits growth of prostate cancer cells.

HY-P99517

Voxalatamab
JNJ-63898081
CD3 Cancer

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research.

Voxalatamab JNJ-63898081	CD3	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research.

HY-16247

Apoptone HE3235	Others	Cancer
Apoptone, synthetic analogue of 3β-androstanediol, is an orally bioavailable anticancer agent. Apoptone is active in rodent models of prostate and breast cancer.

HY-N10265

Stephacidin B	Endogenous Metabolite	Cancer
Stephacidin B is a fungal metabolite. Stephacidin B shows in vitro cytotoxicity against a panel of human tumor cell lines. Stephacidin B shows the strongest cytotoxicity against testosterone-dependent prostate LNCaP cancer cells.

HY-103711

Estramustine	Microtubule/Tubulin	Cancer
Estramustine is an antineoplastic agent. Estramustine depolymerizes microtnbules by binding to tubulin 1, exhibits antimitotic activity with an IC₅₀ value of ~16 μM for mitosis of DU 145 cells. Estramustine blocks cells at mitosis in prostate tumor xenografts.

HY-W017186

ALDH1A3-IN-3	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH1A3-IN-3 (compound 16) is a potent inhibitor of ALDH1A3, with an IC₅₀ of 0.26 μM. ALDH1A3-IN-3 is also a good ALDH3A1 substrate. ALDH1A3-IN-3 can be used for the research of prostate cancer.

HY-147287

Glu-urea-Glu-NHS ester	Others	Cancer
Glu-urea-Glu-NHS ester (compound 21) is an activated N-hydroxysuccinamide (NHS) ester of Glu-urea-Glu which can be used as a pharmacophore for linking with prostate specific membrane antigen (PSMA) inhibitors.

HY-103184

Proxalutamide GT0918; Pruxelutamide	Androgen Receptor SARS-CoV	Cancer
Proxalutamide (GT0918) is an orally active potent androgen receptor (AR) antagonist. Proxalutamide (GT0918) can be used in the study for prostate cancer and COVID-19.

HY-16375

Ozarelix D-63153	GnRH Receptor Apoptosis	Cancer
Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer.

HY-118134

Hepln-13
Others Cancer

Hepln-13 is a potent and orally active Hepsin inhibitor with an IC₅₀ of 0.33 µM. Hepln-13 can be used for the research of metastatic prostate cancer.

Hepln-13	Others	Cancer
Hepln-13 is a potent and orally active Hepsin inhibitor with an IC₅₀ of 0.33 µM. Hepln-13 can be used for the research of metastatic prostate cancer.

HY-136582

Masofaniten Androgen receptor-IN-2	Androgen Receptor	Cancer
Masofaniten (Androgen receptor-IN-2) is a potent and orally active androgen receptor inhibitor. Masofaniten has antitumor activity against prostate cancer.

HY-139453

LP-184	Others	Cancer
LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2).

HY-152241

DS-9300	Histone Acetyltransferase	Cancer
DS-9300 is a potent, orally active, selective EP300/CBP HAT inhibitor with an IC₅₀ value of 28 nM. DS-9300 has anticancer activity and can be used in prostate cancer disease research.

HY-117669

VPC-14228	Androgen Receptor	Cancer
VPC-14228 is a potent androgen receptor DNA binding domain (AR-DBD) inhibitor that interferes with the interaction of AR with androgen response elements and effectively blocks AR transcriptional activity. VPC-14228 can be used in prostate cancer research.

HY-126412

Neochamaejasmine A	Apoptosis	Cancer
Neochamaejasmine A is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L.. Neochamaejasmine A inhibits proliferation, induces cell cycle arrest and apoptosis in tumor cells. Neochamaejasmine A can be used in the research of cancers such as prostate cancer, hepatoma cancer.

HY-145388

AU-15330	PROTACs Epigenetic Reader Domain	Cancer
AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity.

HY-W018723

4-Aminobenzamidine dihydrochloride p-Aminobenzamidine dihydrochloride	Ser/Thr Protease	Cancer
4-Aminobenzamidine (p-Aminobenzamidine) dihydrochloride is a strong trypsin inhibitor, also acting as a relatively weak urokinase type plasminogen activator (uPA) inhibitor (K_i=82 μM). 4-Aminobenzamidine can inhibit growth of a human prostate tumor in SCID mice.

HY-146396

Anticancer agent 51	Others	Cancer
Anticancer agent 51 (compound 3d) is a potent anticancer agent with an K_i of 731.62 nM. Anticancer agent 51 shows anticancer activity. Anticancer agent 51 has the potential for the research of prostate cancer.

HY-43869

Vipivotide tetraxetan Ligand-Linker Conjugate PSMA-617 Ligand-Linker Conjugate	ADC Linker	Cancer
Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is composed of a linker and Glutamate-urea-Lysine, can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine is is the selective pharmacophore to bind to prostate specific membrane antigen (PSMA).

HY-146397

TD-802	PROTACs Androgen Receptor	Cancer
TD-802 (Compound 33c) is an androgen receptor (AR) PROTAC degrader with good microsomal stability. TD-802 has good antitumor efficacy in vivo and can be used for metastatic castration-resistant prostate cancer research.

HY-N6601

Pomolic acid Randialic acid A	Apoptosis	Cancer
Randialic acid A (Pomolic acid) is a pentacyclic triterpene isolated from Euscaphis japonica (Tunb.). Randialic acid A (Pomolic acid) inhibits tumor cells growth and induces cell apoptosis. Randialic acid A (Pomolic acid) has a potential for the treatment of prostate cancer (PC).

HY-148377

Abiraterone sulfate N-oxide	Others	Cancer
Abiraterone sulfate N-oxide is a carboxylic acid. Abiraterone sulfate N-oxide also is a major metabolite of Abiraterone (HY-70013). Abiraterone sulfate N-oxide can be used for the research of prostate cancer.

HY-139970

VPC-13789	Androgen Receptor	Cancer Endocrinology
VPC-13789 is a potent, selective, and orally bioavailable antiandrogen. VPC-13789 can be used for the research of castration-resistant prostate cancer (CRPC) therapeutics. VPC-13789 inhibits androgen receptor (AR) transcriptional activity in LNCaP cells (IC₅₀=0.19 μM).

HY-13702

Nilutamide Nilandron; RU 23908	Androgen Receptor Parasite	Cancer Infection Endocrinology
Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties.

HY-17423E

Abacavir hydrochloride	HIV Apoptosis Reverse Transcriptase Telomerase	Cancer Infection
Abacavir hydrochloride is a competitive, orally active nucleoside reverse transcriptase inhibitor. Abacavir hydrochloride can inhibits the replication of HIV. Abacavir hydrochloride shows anticancer activity in prostate cancer cell lines. Abacavir hydrochloride can trespass the blood-brain-barrier and suppresses telomerase activity.

HY-17423

Abacavir	HIV Reverse Transcriptase Telomerase Apoptosis	Cancer Infection
Abacavir is an orally active and competitive nucleoside reverse transcriptase inhibitor. Abacavir can inhibits the replication of HIV. Abacavir shows anticancer activity in prostate cancer cell lines. Abacavir can trespass the blood-brain-barrier and suppresses telomerase activity.

HY-N2908

Atraric acid Methyl atrarate	Androgen Receptor NO Synthase p38 MAPK NF-κB	Cancer Inflammation/Immunology
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases.

HY-N2059

Santalol	Others	Cancer
Santalol is a mixture of α and β-isomer santalol. α-santalol is isolated from sandalwood oil. α-santalol is a promising anti-cancer agent against cancers such as oral, breast, prostate and skin cancer.

HY-111145

RD162	Androgen Receptor	Cancer
RD162, a diarylthiohydantoin, is an orally active non-steroidal antiandrogen (NSAA). RD162 specifically binds to androgen receptor (AR). RD162 induces tumor regression in mouse models of castration-resistant human prostate cancer.

HY-128172

TRPM4-IN-2 NBA	TRP Channel	Cancer
TRPM4-IN-2 (NBA) is a potent transient receptor potential melastatin 4 (TRPM4) inhibitor with an IC₅₀ value of 0.16 μM. TRPM4-IN-2 can be used for researching prostate cancer and colorectal cancer.

HY-16079

AZD3514	Androgen Receptor	Cancer
AZD3514 is an orally activie and selective androgen receptor (AR) inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC₅₀ value of 5.75. AZD3514 can be used for the research of prostate cancer.

HY-108250

(R)-Bicalutamide	Androgen Receptor	Cancer
(R)-Bicalutamide is the (R)-enantiomer of Bicalutamide (HY-14249). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer.

HY-137193

5,6-Dihydroabiraterone	Drug Metabolite	Cancer
5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer).

HY-17423B

Abacavir monosulfate	HIV Reverse Transcriptase Telomerase Apoptosis	Cancer Infection
Abacavir monosulfate is a competitive, orally active nucleoside reverse transcriptase inhibitor. Abacavir monosulfate can inhibits the replication of HIV. Abacavir monosulfate shows anticancer activity in prostate cancer cell lines. Abacavir monosulfate can trespass the blood-brain-barrier and suppresses telomerase activity.

HY-138555

PROTAC BRD4 Degrader-8	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-8 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC₅₀s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.

HY-138634

PROTAC BRD4 Degrader-11	PROTACs Epigenetic Reader Domain ADC Cytotoxin	Cancer
PROTAC BRD4 Degrader-11 (compound 9a) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-11 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 0.23 nM and 0.38 nM, respectively.

HY-138637

PROTAC BRD4 Degrader-14	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-14 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC₅₀s of 1.8 nM and 1.7 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-14 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.

HY-138633

PROTAC BRD4 Degrader-10	PROTACs Epigenetic Reader Domain ADC Cytotoxin	Cancer
PROTAC BRD4 Degrader-10 (compound 8b) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-10 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 1.3 nM and 18 nM, respectively.

HY-B1150

Clofoctol	Bacterial SARS-CoV Antibiotic	Cancer Infection
Clofoctol is a bacteriostatic antibiotic. Clofoctol is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria. Clofoctol is only functional against Gram-positive bacteria and can penetrate into human lung tissue. Clofoctol is also an inhibitor of prostate cancer. Clofoctol has antiviral potency.

HY-132292

ARD-2128	PROTACs Androgen Receptor	Cancer
ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.

HY-17423A

Abacavir sulfate Abacavir Hemisulfate; ABC sulfate	Reverse Transcriptase HIV Telomerase Apoptosis	Infection
Abacavir sulfate (Abacavir Hemisulfate) is a competitive, orally active nucleoside reverse transcriptase inhibitor. Abacavir sulfate can inhibits the replication of HIV. Abacavir sulfate shows anticancer activity in prostate cancer cell lines. Abacavir sulfate can trespass the blood-brain-barrier and suppresses telomerase activity.

HY-114402

ARD-69	Androgen Receptor PROTACs	Cancer
ARD-69 (compound 34) is a potent PROTAC androgen receptor degrader. ARD-69 induces degradation of androgen receptor (AR) protein in AR-positive prostate cancer cell lines. ARD-69 suppresses AR-regulated gene expression.

HY-B0661

Tamsulosin (R)-(-)-YM12617 free base; LY253351 free base	Adrenergic Receptor Endogenous Metabolite	Cancer Endocrinology Neurological Disease
Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α₁-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models.

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.

HY-N10578

Genkwadaphnin	Others	Cancer
Genkwadaphnin is a daphnane diterpenoid, targeting of importin-β1 to reduce the nuclear accumulation of key CRPC drivers, and shut down their downstream oncogenic signaling. Genkwadaphnin shows potent anti-tumor activity and inhibits castration-resistant prostate cancer (CRPC) in vivo in mice.

HY-P0056

Histrelin	GnRH Receptor	Cancer
Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis.

HY-110127

NU9056	Histone Acetyltransferase Apoptosis	Cancer
NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells.

HY-144669

ALDH1A3-IN-2	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC₅₀ of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer diseases.

HY-144671

ALDH3A1-IN-2	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH3A1-IN-2 (Compound 19) is a potent inhibitor of ALDH3A1 with an IC₅₀ of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH3A1-IN-2 has the potential for the research of cancer diseases.

HY-146170

Anticancer agent 69	Reactive Oxygen Species EGFR Apoptosis	Cancer
Anticancer agent 69 (Compound 34), a potent and selective anticancer agent , potently and selectively inhibits human prostate cancer cell line PC3 (IC₅₀=26 nM). Anticancer agent 69 increases ROS level, down-regulates EGFR and induces apoptosis.

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).

HY-116501

VPC-14449	Androgen Receptor	Cancer
VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC₅₀ of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer.

HY-106954

Upidosin Rec 15/2739; Recordati 15/2739; SB 216469	Adrenergic Receptor	Inflammation/Immunology
Upidosin (Rec 15/2739) is an α-1 adrenoceptor (α-1 AR) antagonist. Upidosin shows moderate selectivity for the α-1A AR subtype. Upidosin shows uroselectivity in urethra and prostate with a K_b value of 2-3 nM higher than in ear artery and aorta with a K_b value of 20-100 nM. Upidosin inhibits [3H]prazosin binding to cloned human α-1A adrenergic receptor. Upidosin can be used for the research of urethral obstruction.

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).

HY-D1676

Thymolphthalein monophosphate disodium hydrate	Phosphatase	Others
Thymolphthalein monophosphate disodium hydrate is a chromogenic substrate for the determination of acid phosphatase and alkaline phosphatase. Thymolphthalein is released during the reaction, increases the pH of the medium for easy detection, produces color and stops hydrolysis. Thymolphthalein monophosphate disodium hydrate can be used for the specific detection of prostatic phosphatase in serum.

HY-142743

Y08175	Epigenetic Reader Domain	Cancer
Y08175 is a potent CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC₅₀s of 37 and 178.15 nM against CBP bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer.

HY-122605

TRPM4-IN-1 CBA	TRP Channel	Cancer Cardiovascular Disease
TRPM4-IN-1 (CBA) is a potent and selective inhibitor of the cation channel TRPM4, with an IC₅₀ of 1.5 μM. TRPM4-IN-1 can be used for the research of cardiac diseases and prostate cancer.

HY-139294

PROTAC BRD4 Degrader-15	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-15 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC₅₀s of 7.2 nM and 8.1 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-15 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.

HY-145709

Ar-V7-IN-1	Androgen Receptor	Cancer
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications, in particular cancers such as prostate cancer (extracted from patent WO2018114781A1, compound 43).

HY-100886

BAY1082439	PI3K Apoptosis	Cancer
BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth.

HY-139180

PRGL493	Others	Cancer
PRGL493 is a potent and selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research.

HY-135671

AhR modulator-1	Aryl Hydrocarbon Receptor VEGFR Estrogen Receptor/ERR	Cancer Endocrinology
AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus.

HY-138635

PROTAC BRD4 Degrader-12	PROTACs Epigenetic Reader Domain ADC Cytotoxin	Cancer
PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 0.39 nM and 0.24 nM, respectively.

HY-122611A

CSRM617 hydrochloride	Androgen Receptor Apoptosis	Cancer
CSRM617 hydrochloride is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor) with a K_d of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. CSRM617 hydrochloride induces apoptosis by appearance of cleaved Caspase-3 and PARP. CSRM617 hydrochloride is well tolerated in the prostate cancer mouse model

HY-138636

PROTAC BRD4 Degrader-13	PROTACs Epigenetic Reader Domain ADC Cytotoxin	Cancer
PROTAC BRD4 Degrader-13 (compound 9d) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-13 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 0.025 nM and 6.0 nM, respectively.

HY-145312

ATR-IN-4	ATM/ATR	Cancer
ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC₅₀s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13).

HY-19527

IST5-002 N6-Benzyladenosine-5'-phosphate	STAT Apoptosis	Cancer
IST5-002, a potent *Stat5a/b* inhibitor, selectively inhibits transcriptional activity of Stat5a/b (IC₅₀s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) cells. IST5-002 can be used in the research of prostate cancer and chronic myeloid leukemia (CML).

HY-142772

Y08284	Epigenetic Reader Domain	Cancer
Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity.

HY-131724

4-(Dodecylamino)phenol p-DDAP; p-Dodecylaminophenol	Apoptosis	Cancer
4-(Dodecylamino)phenol (p-DDAP) is an anticancer agent. 4-(Dodecylamino)phenol has anti-tumor activity and can suppress proliferation, arrest the cell cycle and induce apoptotic cell death. 4-(Dodecylamino)phenol can be used for the research of cancer, such as prostate cancer.

HY-144670

ALDH3A1-IN-1	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC₅₀ of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with docetaxel.

HY-P3229

SN52	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research.

HY-B0371

Terazosin	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.

HY-B0371F

Terazosin hydrochloride	Adrenergic Receptor	Endocrinology Metabolic Disease
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Cancer Endocrinology
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.

HY-146494

Androgen receptor antagonist 5	Androgen Receptor	Cancer
Androgen receptor antagonist 5 (compound 42f) is a potent androgen receptor (AR) antagonist with an IC₅₀ value of 6.17 μM. Androgen receptor antagonist 5 can effectively impair AR nuclear translocation, reducing the levels of nuclear AR, and disrupts AR-mediated gene regulation. Androgen receptor antagonist 5 has antiproliferative activity against LNCaP and exhibits antitumor activity in LNCaP xenograft tumor mice model. Androgen receptor antagonist 5 can be used for researching prostate cancer.

HY-144749

AKR1C3-IN-5	Others	Cancer
AKR1C3-IN-5 (Compound 6e) is a potent inhibitor of AKR1C3. AKR1C3 enzyme is overexpressed in hormone-dependent prostate and breast tumors. AKR1C3-IN-5 derived from drupanin, which exhibits half-maximal inhibitory concentration (IC₅₀) of 9.6 ± 3 μM and selectivity index (SI) of 5.5 against MCF-7 cells.

HY-B0371A

Terazosin hydrochloride dihydrate	Adrenergic Receptor	Endocrinology Metabolic Disease
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.

HY-13673A

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.

HY-118798

DA 3003-2 NSC663285	Phosphatase	Cancer
DA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr¹⁵ Cdc2. DA 3003-2 has the potential for the research of prostate cancer.

HY-143247

Tubulin polymerization-IN-2	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-2 is a potent anticancer agent targeting to β-tubulin with an IC₅₀ value of 0.92 μM. Tubulin polymerization-IN-2 shows promising activity against various leukemia, non-small lung, renal, prostate, and breast cancer cell lines.

HY-P99217

Rilotumumab AMG 102	c-Met/HGFR	Cancer
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.

HY-138632

PROTAC BRD4 Degrader-9	PROTACs Epigenetic Reader Domain ADC Cytotoxin	Cancer
PROTAC BRD4 Degrader-9 (compound 8a) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-9 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 0.86 nM and 7.6 nM, respectively.

HY-107385

Epristeride ONO-9302; SKF105657	5 alpha Reductase	Cancer
Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with K_i value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne.

HY-107640

WAY-170523	MMP	Cancer
WAY-170523 is a potent and selective MMP-13 (matrix metalloproteinase-13) inhibitor, with an IC₅₀ of 17 nM. WAY-170523 can directly attenuate ERK1/2 phosphorylation. WAY-170523 inhibits the invasion of PC-3 cells, can be used for prostate cancer research.

HY-109070

Ralaniten EPI-002	Androgen Receptor	Cancer
Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC₅₀ of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC).

HY-115282A

JNJ-63576253 TRC-253	Androgen Receptor	Cancer
JNJ-63576253 (TRC-253) is a potent and orally active full antagonist of androgen receptor (AR), with IC₅₀s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the research of castration-resistant prostate cancer (CRPC).

HY-P1416

Foxy-5	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.

HY-138280

DTHIB	HSP	Cancer
DTHIB is a direct and selective heat shock factor 1 (HSF1) inhibitor with a K_d of 160 nM for DTHIB binding to the HSF1 DNA binding domain (DBD). DTHIB inhibits HSF1 cancer gene signature (HSF1 CaSig) and selectively stimulates degradation of nuclear HSF1. DTHIB has potently anticancer activities and can be used for prostate cancer research.

HY-151247

GnRH-R antagonist 1	GnRH Receptor	Cancer
GnRH-R antagonist 1 (compound 21a) is an orally safe and membrane-permeable GnRH-R antagonist with high binding affinity (IC₅₀=0.57 nM) and potent in vitro antagonistic activity (IC₅₀=2.18 nM). GnRH-R antagonist 1 can be used in studies of advanced prostate cancer and premature LH peaks preventing.

HY-115747

Namoline	Histone Demethylase	Cancer
Namoline, a γ-pyrone, is a selective and reversible Lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 51 μM in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation. Namoline has the potential for androgen-dependent prostate cancer research.

HY-144094

EZH2-IN-9	Histone Methyltransferase	Cancer
EZH2-IN-9 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-9 has the potential for the research of cancer diseases (extracted from patent WO2021180235A1, compound 17).

HY-143616

EZH2-IN-7	Histone Methyltransferase	Cancer
EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259).

HY-W412264

Pim-1/2 kinase inhibitor 1	Pim	Cancer
Pim-1/2 kinase inhibitor 1 is an orally active pim-1/2 kinase inhibitor. Pim-1/2 kinase inhibitor 1 blocks the ability of Pim kinases to phosphorylate peptides, and inhibits the pim protein kinase directed phosphorylation of 4E-BP1 and p27^Kip1. Pim-1/2 kinase inhibitor 1 can be used in study of cancer, especially prostate cancer.

HY-P1416A

Foxy-5 TFA	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.

HY-115282

JNJ-63576253 free base TRC-253 free base	Androgen Receptor	Cancer
JNJ-63576253 (TRC-253) free base is a potent and orally active full antagonist of androgen receptor (AR), with IC₅₀s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 free base can be used for the research of castration-resistant prostate cancer (CRPC).

HY-122678

LQZ-7F	Survivin Apoptosis	Cancer
LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC₅₀s of 2.99 and 2.47 µM, respectively.

HY-138557

AKR1C3-IN-4	Others	Cancer
AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research.

HY-12830

M-110	Pim	Cancer
M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC₅₀=47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC₅₀s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC₅₀s of 0.6 to 0.9 μM.

HY-13635A

Finasteride acetate MK-906 acetate	5 alpha Reductase	Cancer
Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.

HY-13635

Finasteride MK-906	5 alpha Reductase	Cancer
Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.

HY-112257

S-23	Androgen Receptor	Metabolic Disease
S-23 is an orally active selective androgen receptor modulator (SARM) with a K_i of 1.7 nM. S-23 induces androgen receptor (AR)-mediated transcriptional activation in CV-1 cells. S-23 increases prostate, seminal vesicle, and levator ani muscle weights in castrated rats.

HY-111614

Melengestrol acetate	Progesterone Receptor	Cancer Metabolic Disease
Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research.

HY-13627

Estramustine phosphate sodium	Microtubule/Tubulin Apoptosis	Cancer Endocrinology Inflammation/Immunology
Estramustine phosphate sodium, an estradiol analog, is an orally active antimicrotubule chemotherapy agent. Estramustine phosphate sodium depolymerises microtubules by binding to microtubule associated proteins (MAPs) and/or to tubulin. Estramustine phosphate sodium can interfere mitosis, trigger cell death and induce apoptosis, which can be used for the research of cancer like prostate cancer.

HY-148944

Didocosahexaenoin	Reactive Oxygen Species Apoptosis	Cancer
Didocosahexaenoin, an omega-3 derivative, is a diglyceride of DHA and can be synthesised from DHA triglycerides. Didocosahexaenoin causes significant loss of mitochondrial membrane potential and induces ROS production. Didocosahexaenoin induces apoptosis. Didocosahexaenoin induces stronger cytotoxicity than DHA in human prostate carcinoma cells.

HY-13627A

Estramustine phosphate	Apoptosis Microtubule/Tubulin	Cancer Endocrinology Inflammation/Immunology
Estramustine phosphate, an estradiol analog, is an orally active antimicrotubule chemotherapy agent. Estramustine phosphate depolymerises microtubules by binding to microtubule associated proteins (MAPs) and/or to tubulin. Estramustine phosphate can interfere mitosis, trigger cell death and induce apoptosis, which can be used for the research of cancer like prostate cancer.

HY-144755

MC2652	Histone Demethylase	Cancer
MC2652 (compound 1a) is a potent LSD1 inhibitor. MC2652 displays high inhibiting effects in MV4-11 and NB4 leukaemia cells. MC2652 shows antiproliferative activity against prostate cancer LNCaP cells.

HY-124628

IPI-9119	Fatty Acid Synthase (FASN)	Cancer
IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC₅₀ of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models.

HY-17473

Embelin Embelic acid; Emberine; NSC 91874	IAP NF-κB Apoptosis Autophagy	Cancer
Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC₅₀=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells.

HY-111784

Inobrodib CCS1477	Epigenetic Reader Domain	Cancer
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression.

HY-151576

PRMT5:MEP50 PPI	Others	Cancer
PRMT5:MEP50 PPI is a novel PRMT5:MEP50 protein-protein interaction (PRMT5:MEP50 PPI) inhibitor, shows anti-tumor activity and anti-proliferative activity of lung and prostate cancer cells.

HY-146433

Anticancer agent 55	Apoptosis	Cancer
Anticancer agent 55 is a potent anticancer agent. Anticancer agent 55 shows anticancer activity via reducing the cell viability and cell migration in a dose-dependent manner. Anticancer agent 55 induces apoptosis. Anticancer agent 55 has the potential for the research of prostate cancer and breast cancer.

HY-121524

DJ101	Microtubule/Tubulin	Cancer
DJ101 is a potent and metabolically stable tubulin inhibitor. DJ101 targets the colchicine binding site and overcomes taxane resistance. DJ101 also inhibits melanoma tumor growth and lung metastasis. DJ101 can be used for prostate cancer research.

HY-N0551

Wedelolactone	Caspase Lipoxygenase Apoptosis	Cancer Inflammation/Immunology
Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase (5-Lox) with an IC₅₀ of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer.

HY-119694

Rotenolone	Others	Cancer
Rotenolone is an antiproliferative agent. Rotenolone shows antiproliferative activity against the ovarian cancer A2780, breast cancer BT-549, prostate cancer DU 145, NSCLC NCI-H460, and colon cancer HCC-2998 cell lines, with IC₅₀s of 0.95, 1.6, 2.7, 2.0, and 2.9 μM, respectively.

HY-N1050

Zederone	mTOR	Cancer
Zederone, a germacrane-type sesquiterpene, has potently cytotoxic against human white blood cancer cells and human prostate cancer cells. Zederone significantly inhibits the proliferation and downregulates the protein expressions of mTOR, and phosphorylated p70 S6 kinase (p-p70s6K) in SKOV3 cells.

HY-10617D

Rucaparib acetate AG014699 acetate; PF-01367338 acetate	PARP	Cancer
Rucaparib (AG014699) acetate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib acetate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research.

HY-144636

Atg4B-IN-2	Cathepsin Phospholipase Autophagy	Cancer
Atg4B-IN-2 is a potent competitive Atg4B inhibitor with K_i value of 3.1 μM, also possesses declining PLA₂ inhibitory potency, IC₅₀s of 11 μM and 3.5 μM for Atg4B and PLA₂, respectively. Atg4B-IN-2 enhances the anticancer activity of anti-castration-resistant prostate cancer agents via autophagy inhibition.

HY-107408

SANT 2	Hedgehog	Cancer
SANT 2 is a potent antagonist of Hh-signaling pathway. Hedgehog (Hh) signaling plays an important role in cell signaling of embryonic development and adult tissue homeostasis. SANT 2 has the potential for the research of several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers.

HY-144060

AKT-IN-10	Akt	Cancer
AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4).

HY-147854

B-Raf IN 9	Raf Apoptosis	Cancer
B-Raf IN 9 (compound 8b) is a potent B-Raf inhibitor, with an IC₅₀ of 24.79 nM. B-Raf IN 9 induces apoptosis and shows cell cycle arrest at G2/M phase. B-Raf IN 9 exhibits potent antitumor activity against human prostate cancer PC-3 cell line, with an IC₅₀ of 7.83 µM.

HY-10617C

Rucaparib tartrate AG-014699 tartrate; PF-01367338 tartrate	PARP	Cancer
Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-144059

AKT-IN-9	Akt	Cancer
AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1).

HY-16474

Relugolix TAK-385	GnRH Receptor	Cancer Endocrinology
Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC₅₀=0.33 nM) and monkey receptor (IC₅₀=0.32 nM) compared with TAK-013 (HY-100209). Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al.

HY-P2161B

TAK-683 acetate	Kisspeptin Receptor	Cancer
TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.

HY-P2161A

TAK-683 TFA	Kisspeptin Receptor	Cancer
TAK-683 TFA is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 TFA is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 TFA depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.

HY-P2161

TAK-683	Kisspeptin Receptor	Cancer
TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.

HY-143660

LG308	Microtubule/Tubulin Apoptosis	Cancer
LG308 is a novel synthetic compound with antimicrotubule activity. LG308 induces mitotic phase arrest and inhibits G2/M progression significantly which is associated with the upregulation of cyclin B1 and mitotic marker MPM-2 and the dephosphorylation of cdc2. LG308 also induces *apoptosis and cell death. LG308 significantly suppresses tumor growth. LG308 with antimitotic activity has the potential for the research of prostate* cancer.**

HY-103204

RS100329 hydrochloride	Adrenergic Receptor	Endocrinology
RS100329 hydrochloride is a potent and selective α1A-adrenoceptor antagonist with pK_i values of 9.6, 7.9 and 7.5 for α1A, α1D, and α1B, respectively. RS100329 hydrochloride inhibits reflex urethral contractions. RS100329 hydrochloride can be used in research of benign prostatic hyperplasia.

HY-103591

DUPA(OtBu)-OH	Others	Cancer
DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

HY-124056

AZ10397767	CXCR	Cancer
AZ10397767 is an orally active, selective CXCR2 receptor antagonist with an IC₅₀ of 1 nM. AZ10397767 attenuates the Oxaliplatin (HY-17371)-induced NF-κB transcriptional activity and potentiates Oxaliplatin-induced apoptosis in androgen-independent prostate cancer (AIPC) cells. AZ10397767 significantly inhibits neutrophil recruitment into tumors which then adversely affects tumor growth in vitro and in vivo.

HY-N0790

Lupeol Clerodol; Monogynol B; Fagarasterol	Androgen Receptor Apoptosis	Cancer
Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC).

HY-148761

PSMA I&T	Others	Cancer
PSMA I&T is a potent *PSMA (prostate-specific membrane antigen)* inhibitor. PSMA I&T can be used for SPECT/CT imaging and radionuclide research of prostate cancer (PCa).

HY-147853

B-Raf IN 8	Raf	Cancer
B-Raf IN 8 (compound 7g) is a potent B-Raf inhibitor, with an IC₅₀ of 70.65 nM. B-Raf IN 8 exhibits antitumor activity against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells, with IC₅₀ values of 9.78, 13.78, 18.52 and 29.85 µM.

HY-143235

BRD4 Inhibitor-15	Epigenetic Reader Domain Apoptosis Bcl-2 Family Caspase c-Myc	Cancer
BRD4 Inhibitor-15 (compound 13) is a potent BRD4 inhibitor, with an IC₅₀ of 18 nM. BRD4 Inhibitor-15 induces apoptosis of 22RV1 cells by regulating Bcl-2/Bax proteins and activating caspase-3 signaling pathway. BRD4 Inhibitor-15 down-regulates the c-Myc level in 22RV1 cells. BRD4 Inhibitor-15 can be used for prostate cancer research.

HY-115450

ONO-0300302	LPL Receptor	Cancer Endocrinology
ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research.

HY-130709

PROTAC CDK2/9 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC₅₀=62 nM) and CDK9 (DC₅₀=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC₅₀=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand.

HY-128938

EC1167	ADC Linker	Cancer
EC1167 is the linker for EC1169. EC1169 is prostate-specific membrane antigen targeting-tubulysin conjugate. EC1169 has the potential to treat recurrent metastatic, castration-resistant prostate cancer (MCRPC).

HY-128938A

EC1167 hydrochloride	ADC Linker	Cancer
EC1167 hydrochloride is the linker for EC1169. EC1169 is prostate-specific membrane antigen targeting-tubulysin conjugate. EC1169 hydrochloride has the potential to treat recurrent metastatic, castration-resistant prostate cancer (MCRPC).

HY-P3853

GR 87389	Neurokinin Receptor	Neurological Disease
GR 87389 is a potent NK2 receptor antagonist. GR 87389 antagonized GA 64349-induced smooth muscle strips contractions in a competitive manner in the human detrusor, prostate and prostatic urethra.

HY-N6969

Dicentrine	Adrenergic Receptor	Endocrinology
Dicentrine is a natural product isolated from the plant Stephania epigaea Lo with antihypertensive effect. Dicentrine is an α₁-adrenoceptor antagonist which has effective against human hyperplastic prostates.

HY-136242

UT-34	Androgen Receptor	Cancer Endocrinology
UT-34 is a potent, selective and orally active second-generation pan-androgen receptor (AR) antagonist and degrader with IC₅₀s of 211.7 nM, 262.4 nM and 215.7 nM for wild-type, F876L and W741L AR, respectively. UT-34 binds to ligand-binding domain (LBD) and function-1 (AF-1) domains and requires ubiquitin proteasome pathway to degrade the AR. UT-34 has anti-prostate cancer efficacy.

HY-113289

Brassicasterol	Androgen Receptor HSV Bacterial Drug Metabolite	Cancer Infection
Brassicasterol, a metabolite of Ergosterol, plays a role in the inhibitory effect on bladder carcinogenesis promotion via androgen signaling. Brassicasterol shows dual anti-infective properties against HSV-1 (IC₅₀=1.2 µM) and Mycobacterium tuberculosis, and cardiovascular protective effect. Brassicasterol exerts an anti-cancer effect by dual-targeting AKT and androgen receptor signaling in prostate cancer.

HY-110112

BTT-3033	Integrin Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
BTT-3033 is an orally active conformation-selective inhibitor of α2β1 (EC50: 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen Ⅰ and cell proliferation, and induces cell apoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease.

HY-U00091

Gestonorone Capronate
Gestonorone caproate
Progesterone Receptor Cancer

Gestonorone Capronate is a progestin for the treatment of benign prostatic hypertrophy and endometrial cancer.

HY-N0058

4,5-Dicaffeoylquinic acid Isochlorogenic acid C	HBV Endogenous Metabolite Apoptosis Glucosidase	Infection
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects.

HY-147852

B-Raf IN 7	Raf	Cancer
B-Raf IN 7 (compound 6a) is a potent B-Raf inhibitor, with an IC₅₀ of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC₅₀ values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM.

HY-16993

OICR-9429	Histone Methyltransferase Apoptosis	Cancer
OICR-9429 is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .

HY-101826

ER21355
Phosphodiesterase (PDE) Cancer

ER21355 is an inhibitor of phosphodiesterase 5 (PDE5), used for treatment of prostatic diseases.

HY-N0288

Lycorine	Fatty Acid Synthase (FASN) Virus Protease Bacterial Apoptosis	Cancer Inflammation/Immunology
Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a K_d value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription. Lycorine is also a melanoma vasculogenic inhibitor. Lycorine can be used for the study of prostate cancer and metabolic diseases.

HY-144758

LSD1-IN-17	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 17.2 μM.

HY-144756

LSD1-IN-15	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-15 (compound 1b) is a potent LSD1 inhibitor. LSD1-IN-15 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 9.9 μM.

HY-144757

LSD1-IN-16	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-16 (compound 4b) is a potent LSD1 inhibitor. LSD1-IN-16 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 15.2 μM.

HY-B1012

Quinestrol W-3566	Estrogen Receptor/ERR	Endocrinology Cancer
Quinestrol is a synthetic estrogen, used in hormone replacement therapy, and occasionally to treat breast cancer and prostate cancer

HY-10568

TC-E 5005	Phosphodiesterase (PDE)	Metabolic Disease
TC-E 5005 is a potent and selective PDE10A inhibitor with IC₅₀ values of 7.28, 239, 779, 919, 3,100, and 3,700 nM for PDE10A, 2A, 11A, 5A, 7B and 3A, respectively. TC-E 5005 inhibits adrenergic and neurogenic smooth muscle contractions in the human prostate.

HY-139623

A4B17
Androgen Receptor Cancer

A4B17 is an androgen receptor N-terminal inhibitor for researching androgen-responsive prostate cancer.
HY-13534

Abarelix
R3827; PPI 149
GnRH Receptor Cancer Endocrinology

Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.
HY-143535

HG122
Androgen Receptor Cancer

HG122 promotes androgen receptor (AR) degradation through the proteasome pathway inhibiting the castration-resistant prostate cancer.

HY-B0192S

Alfuzosin-d7 SL 77499-d₇	Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].

HY-146393

PROTAC CYP1B1 degrader-1	PROTACs Cytochrome P450	Cancer
PROTAC CYP1B1 degrader-1 (Compound 6C), a α-naphthoflavone chimera derivative, is able to eliminate cytochrome P450 (CYP)1B1-mediated agent resistance via targeted CYP1B1 degradation, with IC₅₀s of 95.1 and 9838.6 nM for CYP1B1 and CYP1A2, respectively. PROTAC CYP1B1 degrader-1 can be used for the research of CYP1B1-overexpressing prostate cancer.

HY-B0022

Flutamide SCH 13521	Androgen Receptor	Cancer
Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer.

HY-137448

Rezvilutamide
SHR3680
Androgen Receptor Cancer

Rezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer.

HY-113332

Myristoleic acid	Apoptosis Endogenous Metabolite	Inflammation/Immunology
Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells.

HY-147100

α1A-AR Degrader 9c	PROTACs Adrenergic Receptor	Cancer
α1A-AR Degrader 9c (compound 9c) is a potent, selective and reversible α1A-AR (Adrenergic receptor) PROTAC degrader, with a DC₅₀ of 2.86 μM. α1A-AR Degrader 9c induces α1A-AR degradation can be attributed to proteasomal degradation. α1A-AR Degrader 9c inhibits the proliferation of PC-3 cells, with an IC₅₀ of 6.12 μM. α1A-AR Degrader 9c shows antitumor activity, and can be used for prostate cancer research.

HY-13534A

Abarelix Acetate PPI 149 Acetate; R 3827 Acetate	GnRH Receptor	Cancer Endocrinology
Abarelix Acetate (PPI 149 Acetate; R 3827 Acetate) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer research.

HY-U00125

CGP-53153
5 alpha Reductase Endocrinology

CGP-53153 is a steroidal inhibitor of 5 alpha reductase with IC₅₀s of 36 and 262 nM in rat and human prostatic tissue, respectively.

HY-125065

MK-4541	Androgen Receptor 5 alpha Reductase	Cancer Endocrinology
MK-4541 is an orally active and selective androgen receptor (AR) modulator. MK-4541 acts as an antagonist to inhibit 5α-reductase. MK-4541 inhibits proliferation and induces apoptosis in AR positive prostate cancer cells. MK-4541 significantly inhibited the growth of R3327-G prostate tumors in xenograft mouse model.

HY-143332

TRIM24/BRPF1-IN-2	Epigenetic Reader Domain	Cancer
TRIM24/BRPF1-IN-2 (compound 20l) is a potent TRIM24/BRPF1 dual inhibitor, with IC₅₀ values of 0.98 and 1.16 μM, respectively. TRIM24/BRPF1-IN-2 shows TRIM24/BRPF1 bromodomain binding affinity. TRIM24/BRPF1-IN-2 can be used for prostate cancer research.

HY-141860

PSMA-Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.

HY-15194

Dimethylcurcumin ASC-J9; GO-Y025	Androgen Receptor	Cancer
Dimethylcurcumin (ASC-J9) is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.

HY-N7148A

(±)-γ-Tocopherol	Endogenous Metabolite	Cancer
(±)-γ-Tocopherol is an endogenous metabolite present in Blood that can be used for the research of Prostate Cancer and Endometrial Cancer.

HY-N0610A

Cinnamic acid 3-Phenylacrylic acid; β-Phenylacrylic acid	Endogenous Metabolite	Cancer
Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

HY-70006

Galeterone TOK-001; VN-124-1	Cytochrome P450	Cancer
Galeterone (TOK-001) is a multifunctional antiandrogen and CYP17 inhibitor (IC₅₀=47 nM) in castration resistant prostate cancer (CRPC).

HY-117410

Vipivotide tetraxetan PSMA-617	Drug-Linker Conjugates for ADC	Cancer
Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a K_i of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.

HY-136474

Amidephrine (±)-Amidephrine	Adrenergic Receptor	Endocrinology
Amidephrine is a selective agonist of alpha 1-adrenoceptor. Amidephrine inhibits inhibits monopulse field contraction of the vas deferens epithelium and prostate gland.

HY-B0192AS1

Alfuzosin-d7 hydrochloride SL 77499-10-d₇	Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-139893

ERGi-USU-6 mesylate
Others Cancer

ERGi-USU-6 (mesylate) is an ERGi-USU-6 salt derivative that is a new selective inhibitor of ERG positive prostate cancer ( IC₅₀ = 0.089 μM).

HY-111606

DUPA	Ligands for Target Protein for PROTAC	Cancer
DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in agent conjugate to selectively deliver cytotoxic agents to prostate cancer cells.

HY-19960

BCTC
TRP Channel Cancer

BCTC is a potent and specific inhibitor of transient receptor potential cation channel subfamily M member 8 (TRPM8) in prostate cancer (PCa) DU145 cells.

HY-N3755

Dihydroresveratrol	Estrogen Receptor/ERR	Cancer
Dihydroresveratrol, a potent phytoestrogen, is a hormone receptor modulator. Dihydroresveratrol exhibits proliferative effects in androgen-independent prostate and breast cancer cells at picomolar and nanomolar concentrations.

HY-120599

Sabizabulin VERU-111; ABI-231	Microtubule/Tubulin Apoptosis HPV	Cancer
VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC₅₀ of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, and has potential for the treatment of prostate cancer.

HY-132896

KDM4-IN-3	Histone Demethylase	Cancer
KDM4-IN-3 is a KDM4 inhibitor that exhibits improved potency in biochemical assays, is cell-permeable, and kills prostate cancer cells at low micromolar concentrations.

HY-103687

Abiraterone metabolite 1 3β-OH-5α-Abi	Drug Metabolite	Cancer
Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal agent, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.

HY-14249S

Bicalutamide-d4	Androgen Receptor Autophagy	Cancer
Bicalutamide-d₄ is the deuterium labeled Bicalutamide. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer[1].

HY-111503

Y06137	Epigenetic Reader Domain	Cancer
Y06137 is a potent and selective BET inhibitor for treatment of castration-resistant prostate cancer (CRPC). Y06137 binds to the BRD4(1) bromodomain with a K_d of 81 nM.

HY-152520

RLA-5331	Androgen Receptor	Cancer
RLA-5331 is an iron activator containing anti-androgen. RLA-5331 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line.

HY-152512

RLA-4842	Androgen Receptor	Cancer
RLA-4842 is an iron activator containing anti-androgen. RLA-4842 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line.

HY-101017

Palmitoylcarnitine chloride	Endogenous Metabolite	Cancer Inflammation/Immunology
Palmitoylcarnitine chloride is a fatty acid-derived mitochondrial substrate, and selectively decreases cell survival in colorectal and prostate cancer cells by affecting on pro-inflammatory pathways, Ca²⁺ influx, and DHT-like effects.

HY-149927

Antitumor agent-91	Others	Cancer
Antitumor agent-91 is a cyclic phosphate ester derivative with anticancer and anti-proliferative activities. Antitumor agent-91 has potential application in human castration resistant prostate cancer and pancreatic cancer.

HY-13702S

Nilutamide-d6	Isotope-Labeled Compounds Androgen Receptor	Cancer
Nilutamide-d₆ (Nilandron-d6) is the deuterium labeled Nilutamide. Nilutamide (Nilandron) is a non-steroidal anti-androgen agent proposed in the research of metastatic prostatic carcinoma[1][2].

HY-N0610AS

Cinnamic acid-d6 3-Phenylacrylic acid-d₆; β-Phenylacrylic acid-d₆	Endogenous Metabolite	Cancer
Cinnamic acid-d₆ is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

HY-13626

Spisulosine ES-285	PKC	Cancer
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation.

HY-141729

Biotin-NH-PSMA-617	Fluorescent Dye	Cancer
Biotin-NH-PSMA-617 is a biotin-tagged PSMA-617. PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA), which is directly expressed by the tumor cells .

HY-13607A

(rel)-BMS-641988	Androgen Receptor	Cancer
(rel)-BMS-641988 is a relative configuration of BMS-641988. BMS-641988 is a potent nonsteroidal androgen receptor antagonist. BMS-641988 has the potential for the research of prostate cancer.

HY-15214A

CARM1-IN-3 dihydrochloride	Histone Methyltransferase	Cancer
CARM1-IN-3 dihydrochloride (compound 17b) is a potent and selective co-activator associated arginine methyltransferase (CARM1) inhibitor with IC₅₀ values of 0.07, >25 µM for CARM1 and CARM3, respectively.

HY-12364

C75	Fatty Acid Synthase (FASN)	Cancer
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM. C75 is a potent CPT1A activator.

HY-125170

Galiellalactone	STAT	Cancer
Galiellalactone is a is a small non-toxic and non-mutagenic fungal metabolite, a selective inhibitor of STAT3 signaling, with an IC₅₀ of 250-500 nM. Galiellalactone can be used to research castration-resistant prostate cancer.

HY-109564

5α-Pregnane-3β,6α-diol-20-one	Drug Metabolite	Cancer
5α-Pregnane-3β,6α-diol-20-one is a mitogenic metabolite of progesterone, and it can be produced in starved androgen-responsive prostate cancer cells.

HY-B0661A

Tamsulosin hydrochloride (R)-(-)-YM12617; LY253351	Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology Cancer
Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α₁-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models.

HY-15694

SMIP004	E1/E2/E3 Enzyme Apoptosis	Cancer
SMIP004 is a SKP2 E3 ligase inhibitor, which downregulates SKP2 and to stabilise p27. SMIP004 is a cancer cell selective apoptosis inducer of human prostate cancer cells.

HY-13626S

Spisulosine-d3	PKC	Cancer
Spisulosine-d₃ is deuterium labeled Spisulosine. Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKC

HY-14281

Trilostane Win 24540	Others	Endocrinology Cancer
Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer.

HY-111237

Butyrolactone I Olomoucin	CDK	Cancer
Butyrolactone I is an ATP-competitive inhibitor of CDK1 as a secondary metabolite from A. terreus. Butyrolactone I has antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines.

HY-111895B

Macropa-NH2 TFA	Others	Others
Macropa-NH2 TFA is the precursor of Macropa-NCS. Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases.

HY-N7045

Isosilybin B	Androgen Receptor Apoptosis	Cancer
Isosilybin B, a flavonolignan isolated from Silybum marianum, has anti-prostate cancer (PCA) activity via inhibiting proliferation and inducing G1 phase arrest and apoptosis. Isosilybin B causes androgen receptor (AR) degradation.

HY-10088

Zibotentan ZD4054	Endothelin Receptor Apoptosis	Cancer Endocrinology
Zibotentan (ZD4054) is a potent, selective and orally active endothelin A (ET_A) receptor antagonist with a K_i of 13 nM. Zibotentan has no inhibitory effect on ETB. Zibotentan has anticancer effects and can be used for castration-resistant prostate cancer (CRPC) research.

HY-16187

EL-102	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer.

HY-148777

A031	PROTACs Androgen Receptor	Cancer
A031 is a highly effective PROTAC androgen receptor (AR) degrader with an IC₅₀ value less than 0.25 μM for AR protein degradation. A031 has an inhibitory effect on tumor growth in zebrafish with human prostate cancer (VCaP).

HY-10528

Tasquinimod ABR-215050	HDAC	Cancer
Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment. Tasquinimod binds to the regulatory Zn²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor.

HY-144667

ALDH1A3-IN-1	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH1A3-IN-1 (Compound 14) is a potent ALDH1A3 inhibitor, with an IC₅₀ of 0.63 µM and a K_i of 0.46 µM. ALDH1A3-IN-1 can be studied in prostate cancer.

HY-146574

AKR1C3-IN-7
Others Cancer

AKR1C3-IN-7 (Compound 13) is a potent, selective AKR1C3 inhibitor with an IC₅₀ of 0.19 μM. AKR1C3-IN-7 shows antitumor activity.
HY-146575

AKR1C3-IN-8
Others Cancer

AKR1C3-IN-8 (Compound 5) is a potent, selective AKR1C3 inhibitor with an IC₅₀ of 0.069 μM. AKR1C3-IN-8 shows antitumor activity.

HY-146573

AKR1C3-IN-6	Others	Cancer
AKR1C3-IN-6 (Compound 1) is a potent, selective AKR1C3 inhibitor with IC₅₀ values of 0.31 μM and 73.23 μM against AKR1C3 and AKR1C2, respectively. AKR1C3-IN-6 shows antitumor activity.

HY-N0819

Raddeanin A	Apoptosis	Cancer
Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway.

HY-141524

RMC-3943
SHP2 Phosphatase Cancer

RMC-3943 is an allosteric SHP2 inhibitor (inhibition of full-length SHP2 in biochemical assay, IC₅₀ = 2.19 nM).

HY-129746

Arylquin 1	Apoptosis	Cancer
Arylquin 1, a prostate-apoptosis-response-4 (Par-4) secretagogue, targets vimentin to induce Par-4 secretion. Arylquin 1 induces non-apoptotic cell death in cancer cells through the induction of lysosomal membrane permeabilization (LMP).

HY-103385

NCX4040 NO-Aspirin	Apoptosis	Cancer Inflammation/Immunology
NCX4040 (NO-Aspirin), a non-steroidal anti-inflammatory drug (NSAID), is a nitric oxide (NO) releasing form of Aspirin. NCX4040 induces apoptosis in PC3 metastatic prostate cancer cells. NCX4040 has anti-inflammatory and anti-cancer effects.

HY-114988

PGE-M tetranor-PGEM	Endogenous Metabolite	Cancer Inflammation/Immunology
PGE-M is a metabolite of prostaglandin E₂ (PEG₂) as a biomarker of inflammation and cancer including advanced colorectal neoplasia, ovarian cancer, prostate cancer and so on. Urinary PGE-M is positively associated with obesity, smoking and lung metastases with breast cancer.

HY-B0661AS1

Tamsulosin-d4 hydrochloride (R)-(-)-YM12617-d₄; LY253351-d₄	Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Tamsulosin-d₄ (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-B0661AS

Tamsulosin-d5 hydrochloride	Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Tamsulosin-d₅ (hydrochloride) is the deuterium labeled Tamsulosin hydrochloride. Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-132222

SET2	TRP Channel	Cancer
SET2 is a selective TRPV2 antagonist (IC₅₀=0.46 μM). SET2 blocks the TRP channel and suppresses prostate cancer cells migration. SET2 reduces the lysophosphatidic acid (LPA, a TRPV2 activator)-induced cytoplasmic calcium increases.

HY-109050

Alobresib GS-5829	Epigenetic Reader Domain	Cancer
Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research.

HY-136990

GLPG0259	Others	Cancer
GLPG0259 is a ATP-competitive inhibitor of MAPK-activated protein kinase 5 (MK5) with oral activity. GLPG0259 reduces inflammation and bone destruction in a mouse model of collagen-induced arthritis. GLPG0259 also inhibited the metastasis of prostate cancer (PCa) cells.

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613)	GnRH Receptor	Cancer Endocrinology
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model.

HY-19702

PKR activator 3	Pyruvate Kinase	Cancer Metabolic Disease Inflammation/Immunology
PKR activator 3 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR activator 3 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia.

HY-N1338

Royleanone NSC 122417	mTOR Akt	Cancer
Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits mTOR/PI3/AKT signaling pathway in LNCaP prostate cancer cells.

HY-12842

UC-112	IAP Apoptosis	Cancer
UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor; potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM).

HY-111895A

Macropa-NH2 hydrochloride	Others	Cancer
Macropa-NH2 hydrochloride is the precursor of Macropa-NCS. Macropa-NCS is conjugated to Anti-Human HER2 (HY-P9907) as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases.

HY-N0610AS2

Cinnamic acid-13C3 3-Phenylacrylic acid-¹³C₃; β-Phenylacrylic acid-¹³C₃	Isotope-Labeled Compounds Endogenous Metabolite	Cancer
Cinnamic acid-¹³C₃ (3-Phenylacrylic acid-¹³C₃) is the ¹³C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

HY-N7043

Isosilybin A	Apoptosis	Cancer
Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis.

HY-W058849

MT 63-78	AMPK mTOR Apoptosis	Cancer
MT 63-78 is a specific and potent direct AMPK activator with an EC₅₀ of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects.

HY-124573

OBI-3424 TH-3424	DNA Alkylator/Crosslinker	Cancer
OBI-3424 (TH-3424) is a proagent that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. OBI-3424 can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research.

HY-146230

VEGFR-2-IN-26	VEGFR	Cancer
VEGFR-2-IN-26 (compound 5h) is a highly potent VEGFR-2 inhibitor with an IC₅₀ value of 15.5 nM. VEGFR-2-IN-26 has good antiproliferative activity against the leukemic, non-small lung, CNS, ovarian, renal, prostate and breast cancer cells.

HY-13215

Avasimibe CI-1011; PD-148515	Acyltransferase	Cancer
Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC₅₀s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively. Avasimibe can be used for the research of prostate cancer.

HY-N2415

Podophyllotoxone	Microtubule/Tubulin	Cancer
Podophyllotoxone is isolated from the roots of Dysosma versipellis and has anti-cancer activities.Podophyllotoxone is able to inhibit the tubulin polymerization.

HY-15159

Cyclapolin 9	Polo-like Kinase (PLK)	Cancer
Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 500 nM. Cyclapolin 9 is inactive against other kinases.

HY-122234

VPC-18005	Others	Cancer
VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, and disrupts the ERG binding to DNA. VPC-18005 is a potent inhibitor of luciferase activity.

HY-141487

CLP-3094	Androgen Receptor	Metabolic Disease Inflammation/Immunology
CLP-3094 is a potent BF3 (binding function 3)-directed inhibitor of the androgen receptor (AR). CLP-3094 inhibits AR transcriptional activity (IC₅₀=4 μM). CLP-3094 is a selective, potent GPR142 antagonist.

HY-W013249

Boc-piperazine-benzoic acid	PROTAC Linkers	Cancer
Boc-piperazine-benzoic acid is a PROTAC linker and can be used in the synthesis of PROTACs, such as PROTAC androgen receptor (AR) degrader ARD-2128 (HY-13229).

HY-114668

Camptothecin-20(S)-O-propionate Camptothecin-20-O-propionate	Topoisomerase	Cancer
Camptothecin-20(S)-O-propionate (CZ48), the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate (CZ48) is a topoisomerase-Ι inhibitor.

HY-139436

ARD-2585
PROTACs Androgen Receptor Cancer

ARD-2585 is an exceptionally potent and orally active PROTAC degrader of androgen receptor.

HY-12023

GTx-007 S-4	Androgen Receptor	Cancer
GTx-007 (S-4) is an orally active and selective nonsteroidal androgen receptor (AR) modulator (SARM) and a partial agonist, with K_i of 4 nM. GTx-007 (S-4) is identified as SARMs with potent and tissue-selective in vivo pharmacological activity.

HY-150102

EPI-7170	Androgen Receptor	Cancer
EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC).

HY-148838

c-Myc inhibitor 8	c-Myc	Cancer
c-Myc inhibitor 8 (compound 56) is a c-Myc inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research.

HY-B0371S

Terazosin-d8	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

HY-133020

ARD-266	PROTACs Androgen Receptor	Cancer
ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM.

HY-147261

B026	Histone Acetyltransferase	Cancer
B026 is a selective, potent, orally active p300/CBP histone acetyltransferase (HAT) inhibitor with IC₅₀ values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines.

HY-136938

NEO2734 EP31670	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
NEO2734 (EP31670) is an orally active dual p300/CBP and BET bromodomain selective inhibitor, with IC₅₀ values of <30 nM for both p300/CBP and BET bromodomains. NEO2734 is active in SPOP mutant and wild-type prostate cancer.

HY-117756

Piflufolastat DCFPYL	Others	Others
Piflufolastat (DCFPYL) can be used to the preparation of piflufolastat F 18 (DCFPyL F-18). piflufolastat F 18. Piflufolastat F-18 is an 18F-labelled diagnostic imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA).

HY-114372

Lycopodine	Lipoxygenase Caspase Apoptosis	Cancer
Lycopodine, a pharmacologically important bioactive component derived from Lycopodium clavatumspores, triggers apoptosis by modulating 5-lipoxygenase, and depolarizing mitochondrial membrane potential in refractory prostate cancer cells without modulating p53 activity. Lycopodine inhibits proliferation of HeLa cells through induction of apoptosis via caspase-3 activation.

HY-153396

Acid Ceramidase-IN-2	Ceramidase	Cancer
Acid Ceramidase-IN-2 (compound 1) is an acid ceramidase inhibitor with potentially antiproliferative and cytostatic activities. Moreover, human acid ceramidase is overexpressed in prostate cancer cells, indicating potential anti-tumor effect of Acid Ceramidase-IN-2. And Acid Ceramidase-IN-2 hydrolysis can be inhibited by 3 a-ketoamides GT85, GT98 and GT99 inhibits in vitro.

HY-50901

ONO-AE3-208 AE 3-208	Prostaglandin Receptor	Cancer Endocrinology
ONO-AE3-208 is a selective and orally active EP4 receptor antagonist with a K_i of 1.3 nM. ONO-AE3-208 shows less potently affects EP3, FP, and TP receptors (K_i of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.

HY-10617

Rucaparib phosphate AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-10617A

Rucaparib AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research.

HY-147734

Calpain Inhibitor-2	Others	Cancer
Calpain inhibitors are lipophilic and show moderate to good antiproliferative activity in vitro compared with melanoma cell lines (a-375 and b-16f1) and PC-3 prostate cancer cells. In addition, a member of this group (compound 3) expressed 2 μ M concentration inhibited the invasion of DU-145 cells by 80%.

HY-152479

Topoisomerase IIα-IN-7	Topoisomerase	Cancer
Topoisomerase IIα-IN-7 is an DNA topoisomerase IIα inhibitor with an IC₅₀ value of 7.7 µM. Topoisomerase IIα-IN-7 has broad-spectrum cytotoxicity to leukemia, lung, colon, melanoma, ovarian, kidney, prostate and breast cancer cells. Topoisomerase IIα-IN-7 has metabolic stability.

HY-13721

Phenoxodiol Idronoxil; Dehydroequol; Haginin E	Caspase Apoptosis Topoisomerase	Cancer
Phenoxodiol (Idronoxil), a synthetic analog of Genestein, activates the mitochondrial caspase system, inhibits XIAP (an apoptosis inhibitor), and sensitizes the cancer cells to Fas-mediated apoptosis. Phenoxodiol also inhibits DNA topoisomerase II by stabilizing the cleavable complex. Phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle and upregulates p21^WAF1 via a p53 independent manner.

HY-19539

NSC-658497	Ras	Cancer
NSC-658497 is an effective inhibitor of Ras-GEF, SOS1. NSC-658497 binds to SOS1, competitively suppresses SOS1-Ras interaction, and dose-dependently inhibits SOS1 GEF activity. NSC-658497 showed dose-dependent efficacy in inhibiting Ras, downstream signaling activities, and associated cell proliferation.

HY-P3668

[D-Lys6]-LH-RH
GnRH Receptor Cancer Endocrinology

[D-Lys6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH acts as a GnRH receptor agonist.

HY-146027

Androgen receptor antagonist 4	Androgen Receptor	Cancer
Androgen receptor antagonist 4 (Compound AT2) is an androgen receptor (AR) antagonist with an IC₅₀ of 0.15 μM. Androgen receptor antagonist 4 efficiently antagonizes AR transcriptional activity, suppresses downstream target gene of AR, and blocks the DHT-induced AR nuclear translocation. Androgen receptor antagonist 4 shows anticancer activities.

HY-120210

XY018	ROR	Cancer Inflammation/Immunology
XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC₅₀, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD).

HY-146026

Androgen receptor antagonist 3	Androgen Receptor	Cancer
Androgen receptor antagonist 3 (Compound C18) is an androgen receptor (AR) antagonist with an IC₅₀ of 2.4 μM. Androgen receptor antagonist 3 shows anticancer activities.

HY-19319

MI-136	Epigenetic Reader Domain Androgen Receptor Apoptosis	Cancer
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC₅₀ of 31 nM and a K_d of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors.

HY-122611

CSRM617	Androgen Receptor Apoptosis	Cancer
CSRM617 is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor) with a K_d of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. CSRM617 induces apoptosis by appearance of cleaved Caspase-3 and PARP. CSRM617 is well tolerated in the prostate cancer mouse model

HY-111024

2,2,5,7,8-Pentamethyl-6-Chromanol PMC	Androgen Receptor	Cancer
2,2,5,7,8-Pentamethyl-6-Chromanol (PMC) is the anti-oxidant moiety of vitamin E (α-tocopherol). 2,2,5,7,8-Pentamethyl-6-Chromanol has potent androgen receptor (AR) signaling modulation and anti-cancer activity against prostate cancer cell lines.

HY-111614S

Melengestrol acetate-d6	Progesterone Receptor	Cancer Metabolic Disease
Melengestrol acetate-d₆ is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity[1]. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research[2].

HY-111614S2

Melengestrol acetate-d3	Progesterone Receptor	Cancer Metabolic Disease
Melengestrol acetate-d₃ is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity[1]. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research[2].

HY-119344

MS37452	Histone Methyltransferase	Cancer
MS37452 is a potent inhibitor of CBX7 chromodomain binding to H3K27me3, with a K_d of 27.7 μM. MS37452 can derepress transcription of polycomb repressive complex target gene p16/CDKN2A by displacing CBX7 binding to the INK4A/ARF locus in prostate cancer cells.

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-110028

Leelamine hydrochloride	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor	Cancer Endocrinology
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees. Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis^[2,3].

HY-111614S1

Melengestrol acetate-d2	Progesterone Receptor	Cancer Metabolic Disease
Melengestrol acetate-d₂ is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity[1]. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research[2].

HY-102003

Rucaparib monocamsylate AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research.

HY-100348

EPI-001	Androgen Receptor PPAR Apoptosis	Cancer
EPI-001, a selective inhibitor of Androgen Receptor (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC₅₀ of ~6 μM. EPI-001 is also a selective modulator of PPARγ. EPI-001 is active against castration-resistant prostate cancer.

HY-110066

(Z)-Guggulsterone	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR	Cancer
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis. (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection.

HY-118487

OB-24	Others	Cancer
OB-24 is a potent inhibitor of heme oxygenase-1 (HO-1). Heme oxygenase-1, a member of the heat shock protein family, plays a key role as a sensor and regulator of oxidative stress. OB-24 significantly inhibited cell proliferation in vitro and tumor growth and lymph node/lung metastases in vivo. OB-24 has potential for the research of advanced prostate cancer (PCA).

HY-118480

4-MMPB	Lipoxygenase Apoptosis	Cancer
4-MMPB is a selective inhibitor of 15-lipoxygenase, with an IC₅₀ of 18 μM. 4-MMPB has IC₅₀s of 19.5 μM and 19.1 μM for soybean 15-lipoxygenase (SLO) and human 15-lipoxygenase-1 (15-LOX-1), respectively. 4-MMPB has potential for the research of prostate cancer.

HY-16215

Mipsagargin G-202	Drug-Linker Conjugates for ADC	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research.

HY-112083

BAY-3827	AMPK	Cancer
BAY-3827 is a potent and selective AMPK inhibitor with IC₅₀ values of 1.4 nM at low (10 µM ATP concentration) and 15 nM at high (2 mM ATP concentration). BAY-3827 shows over 500-fold selectivity for most of the 331 kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1 and shows strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines.

HY-13604

Cyproterone acetate	Androgen Receptor	Cancer Endocrinology
Cyproterone acetate is an anti-androgen (IC₅₀=7.1 nM) and progestogen synthetic steroid. Cyproterone acetate has affinity with progesteron and with glucocorticoidal receptors.

HY-145259

HDAC6-IN-3	HDAC Histone Demethylase	Cancer
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and LSD1 inhibitor.

HY-70002B

Enzalutamide carboxylic acid MDV3100 carboxylic acid	Drug Metabolite	Cancer
Enzalutamide carboxylic acid (MDV3100 carboxylic acid) is an inactive metabolite of Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist.

HY-123875A

Ralaniten triacetate EPI-506	Androgen Receptor	Cancer
Ralaniten triacetate (EPI-506), the pro-agent of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7.

HY-B0391S1

Naftopidil-d5 KT-611-d₅; BM-15275-d₅	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

HY-13635S

Finasteride-d9 MK-906-d₉	5 alpha Reductase	Cancer
Finasteride-d₉ is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].

HY-133045

VHL Ligand 8	Ligands for E3 Ligase	Cancer
VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM.

HY-135794

11-Ketodihydrotestosterone 11-KDHT; 5α-Dihydro-11-keto testosterone	Androgen Receptor	Endocrinology
11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a K_i of 20.4 nM and an EC₅₀ of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells.

HY-119037

UK-101	Proteasome Apoptosis	Cancer
UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC₅₀ value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC₅₀=15 μM) and β5 subunit (IC₅₀=1 μM), respectivey. UK-101 induces cell apoptosis and can be used for the study of prostate cancer.

HY-133044

Boc-Pip-alkyne-Ph-COOH	PROTAC Linkers	Cancer
Boc-Pip-alkyne-Ph-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-Pip-alkyne-Ph-COOH can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 effectively induces degradation of androgen receptor (AR) protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM.

HY-10211

Tanespimycin 17-AAG; NSC 330507; CP 127374	HSP Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Cancer Infection
Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression.

HY-147874

ANO1-IN-3
Chloride Channel Apoptosis Cancer

ANO1-IN-3 (Compound 3n) is a potent and selective ANO1 inhibitor with an IC₅₀ of 1.23 μM. ANO1-IN-3 induces apoptosis.

HY-135732

SK33	Androgen Receptor	Cancer
SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity.

HY-147868

DC-CPin711	Epigenetic Reader Domain Apoptosis	Cancer
DC-CPin711 is a potent and selective inhibitor of CREB-binding protein (CBP) bromodomain with an IC₅₀ of 0.0626 μM. DC-CPin711 arrests cell cycle at G1 phase and induces apoptosis.

HY-120574

TH1338	Others	Cancer
TH1338 (compound 3b), an orally active camptothecin derivative and a potent chemotherapeutic agent for cancer, demonstrates excellent cytotoxic potency against human tumor cell lines in vitro. TH1338 (compound 3b) possesses significant brain penetration, favorable efflux pump properties, and hematological toxicity profile.

HY-42424

(S,R,S)-AHPC-Me hydrochloride VHL ligand 2 hydrochloride; E3 ligase Ligand 1	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM.

HY-42424A

(S,R,S)-AHPC-Me dihydrochloride VHL ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me dihydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM.

HY-147696

SMTIN-T140	HSP AMPK Reactive Oxygen Species	Cancer
SMTIN-T140 (compound 6a) is a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC₅₀ of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates AMPK. SMTIN-T140 potently suppressed tumor growth without any noticeable in vivo toxicity in a mouse model xenografted with PC3 prostate cancer cells.

HY-112078

(S,R,S)-AHPC-Me VHL ligand 2; E3 ligase Ligand 1A	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM.

HY-114759

MS-PPOH	Cytochrome P450	Cancer Metabolic Disease Neurological Disease
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor. MS-PPOH inhibits CYP2C8 and CYP2C9 with IC₅₀s of 15 and 11 µM, respectively.

HY-14507

YK-4-279	DNA/RNA Synthesis Apoptosis	Cancer
YK-4-279 blocks RNA Helicase A (RHA) binding with EWS-FLI1 (oncogenic protein). YK-4-279 induces apoptosis and shows anti-proliferation activities towards various cancer cells. YK-4-279 has a chiral center and it can be separated into two enantiomers. YK-4-279 can be used for the research of cancer.

HY-135794S

11-Ketodihydrotestosterone-d3 11-KDHT-d₃; 5α-Dihydro-11-keto testosterone-d₃	Androgen Receptor	Endocrinology
11-Ketodihydrotestosterone-d₃ is the deuterium labeled 11-Ketodihydrotestosterone. 11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a Ki of 20.4 nM and an EC50 of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells[1][2].

HY-10071

Y-27632	ROCK Apoptosis	Cancer
Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with K_is of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation.

HY-16474S

Relugolix-d6 TAK-385-d₆	GnRH Receptor	Cancer Endocrinology
Relugolix-d₆ is deuterium labeled Relugolix. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209)[1]. Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al[2].

HY-104040

MKC8866	IRE1	Cancer
MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC₅₀ of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC₅₀ of 0.52 μM and unstresses RPMI 8226 cells with an IC₅₀ of 0.14 μM. MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth.

HY-N0103A

Sophocarpine monohydrate	Autophagy Apoptosis PI3K Akt Influenza Virus	Cancer Infection Inflammation/Immunology
Sophocarpine (monohydrate) is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine (monohydrate) significantly inhibits the growth of gastric cancer (GC) cells through multiple mechanisms such as induction of autophagy, activation of cell apoptosis and down-regulation of cell survival PI3K/AKT signaling pathway. Sophocarpine (monohydrate) has been demonstrated to have anti-tumor activity in various cancer cells, including hepatocellular carcinoma, prostate cancer and colorectal cancer.

HY-N0103

Sophocarpine	Autophagy Apoptosis PI3K Akt Influenza Virus	Cancer Infection Inflammation/Immunology
Sophocarpine is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine significantly inhibits the growth of gastric cancer (GC) cells through multiple mechanisms such as induction of autophagy, activation of cell apoptosis and down-regulation of cell survival PI3K/AKT signaling pathway. Sophocarpine has been demonstrated to have anti-tumor activity in various cancer cells, including hepatocellular carcinoma, prostate cancer and colorectal cancer.

HY-147185

PRMT7-IN-1
Histone Methyltransferase Cancer

PRMT7-IN-1 (Compound 14) is a PRMT7 inhibitor with an IC₅₀ of 2.1 μM. PRMT7-IN-1 shows anticancer activity against different cancer cells.

HY-10122

Silodosin KAD 3213; KMD 3213	Adrenergic Receptor Bacterial	Cancer Endocrinology
Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (K_i=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with K_i values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH.

HY-13991

CCG-1423	Ras Apoptosis	Cancer
CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes.

HY-103345

2-MPPA GPI-5693	Carboxypeptidase	Cancer Neurological Disease
2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC₅₀ of 90 nM.

HY-13591

Piclidenoson IB-MECA; CF-101	Adenosine Receptor Apoptosis	Cancer Inflammation/Immunology
Piclidenoson (IB-MECA) is a first-in-class, orally active and selective A3 adenosine receptor (A3AR) agonist. Piclidenoson exhibits antiproliferative effect and induces apoptosis in different cancer cell types like melanoma, leukemia. Piclidenoson can be used for the research of autoimmune inflammatory diseases and COVID-19.

HY-13963

ZCL278	Ras	Cancer
ZCL278 is a selective Cdc42 modulator that directly binds to Cdc42 and inhibits its functions with K_d of 11.4 μM for Cdc42-ZCL278 affinity in surface plasmon resonance (SPR) experiment.

HY-114250

Cantrixil TRX-E-002-1	Apoptosis	Cancer
Cantrixil (TRX-E-002-1), an active enantiomer of TRX-E-002, is a second-generation super-benzopyran (SBP) compound. Cantrixil increases phosphorylated c-Jun levels resulting in caspase-mediated apoptosis in ovarian cancer cells. Cantrixil has potent pan anti-cancer activity against a broad range of cancer phenotypes.

HY-17503C

Metoprolol fumarate CGP 2175C; Lopressor OROS	Adrenergic Receptor Apoptosis	Cancer Infection Endocrinology Cardiovascular Disease
Metoprolol fumarate (CGP 2175C) is an orally active, selective β1-adrenoceptor antagonist. Metoprolol fumarate shows anti-inflammation, antitumor and anti-angiogenic properties.

HY-17503

Metoprolol	Adrenergic Receptor Apoptosis	Cancer Infection Endocrinology Cardiovascular Disease
Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties.

HY-125108

PHPS1 sodium	SHP2 Phosphatase	Cancer Cardiovascular Disease
PHPS1 sodium is a potent and selective Shp2 inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.

HY-151266

AR antagonist 4	Androgen Receptor	Cancer
AR antagonist 4 (Compound 67-b) is an orally active androgen receptor (AR) antagonist with an IC₅₀ of 246.6 nM against wt-AR, and is also an AR degrader with a DC₅₀ of 2.84 μM.

HY-14452

Fatostatin 125B11	Fatty Acid Synthase (FASN)	Cancer
Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.

HY-B0304

Dapoxetine (S)-(+)-Dapoxetine; LY-210448	Serotonin Transporter	Neurological Disease
Dapoxetine (LY-210448) is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine can be used for the research of premature ejaculation (PE).

HY-B0304A

Dapoxetine hydrochloride LY-210448 hydrochloride	Serotonin Transporter	Neurological Disease
Dapoxetine (LY-210448) hydrochloride is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine hydrochloride can be used for the research of premature ejaculation (PE).

HY-14452A

Fatostatin hydrobromide 125B11 hydrobromide	Fatty Acid Synthase (FASN)	Cancer
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.

HY-15371

Forskolin Coleonol; Colforsin; HL 362	Adenylate Cyclase FXR Autophagy	Cancer Endocrinology Metabolic Disease Inflammation/Immunology
Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase. Forskolin is also an inducer of intracellular cAMP formation. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy.

HY-17503B

Metoprolol tartrate	Adrenergic Receptor Apoptosis	Cancer Infection Endocrinology Cardiovascular Disease
Metoprolol tartrate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol tartrate shows anti-inflammation, antitumor and anti-angiogenic properties.

HY-112368

PHPS1	SHP2 Phosphatase	Cancer Cardiovascular Disease
PHPS1 is a potent and selective Shp2 inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.

HY-125355

SEC	Apoptosis	Cancer
SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation.

HY-17503A

Metoprolol succinate	Adrenergic Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Metoprolol succinate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol succinate shows anti-inflammation, antitumor and anti-angiogenic properties.

HY-15792

(R)-FL118 10,11-(Methylenedioxy)-20(R)-camptothecin	Others	Cancer
(R)-FL118 (10,11-(Methylenedioxy)-20(R)-camptothecin) is the R-enantiomer of FL118 (HY-12486). (R)-FL118 shows anticancer activity.

HY-10181B

Dasatinib monohydrate BMS-354825 monohydrate	Bcr-Abl Src Autophagy Apoptosis	Cancer
Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib monohydrate also induces apoptosis and autophagy.

HY-136342

Antitumor agent-23	Others	Cancer
Antitumor agent-23 is a potent anti-cancer agent with GI₅₀s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity.

HY-10181A

Dasatinib hydrochloride BMS-354825 hydrochloride	Bcr-Abl Src Autophagy Apoptosis	Cancer
Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib hydrochloride also induces apoptosis and autophagy.

HY-13818

Stattic	STAT Apoptosis	Cancer Inflammation/Immunology
Stattic is a potent *STAT3* inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.

HY-10181

Dasatinib BMS-354825	Bcr-Abl Src Autophagy Apoptosis	Cancer
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.

HY-108986

JFD00244
Sirtuin SARS-CoV Cancer

JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2.

HY-110368

BS-181 dihydrochloride	CDK	Cancer
BS-181 dihydrochloride is a potent and selective CDK7 inhibitor (IC₅₀=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC₅₀ values of 880 nM, 3000 nM and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 dihydrochloride inhibits a panel of cancer cells growth (IC₅₀=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 dihydrochloride has the potential for the research of cancer therapy.

HY-17437

Mefloquine Mefloquin	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase	Cancer Infection Metabolic Disease Inflammation/Immunology
Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research.

HY-123295

HDAC3-IN-T247	HDAC	Cancer Infection
HDAC3-IN-T247 is a potent and selective HDAC3 (histone deacetylase 3) inhibitor, with an IC₅₀ of 0.24 µM. HDAC3-IN-T247 induces a selective increase of NF-κB acetylation in HCT116 cells. HDAC3-IN-T247 shows anticancer and antiviral activity. HDAC3-IN-T247 inhibits growth of cancer cells, and activates HIV gene expression in latent HIV-infected cells.

HY-13610

N1,N11-Diethylnorspermine	Caspase	Cancer
N1,N11-Diethylnorspermine (DENSPM) is a potent anticancer agent. N1,N11-Diethylnorspermine is a spermine analog that activates polyamine catabolism. N1,N11-Diethylnorspermine induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine kills glioblastoma multiforme (GBM) cells through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production.

HY-135849

Catalase	Reactive Oxygen Species	Cancer
Catalase is a key enzyme in the metabolism of H₂O₂ and reactive oxygen species (ROS), and its expression and localization is markedly altered in tumors. Free oxygen radical scavenger.

HY-147504

Anticancer agent 63	Apoptosis Caspase Bcl-2 Family	Cancer
Anticancer agent 63 (compound 3h) shows active in reducing the viability of different cancer cell lines, including SW480, HeLa, A549 and MCF-7, with IC₅₀ values at 24 h of 4.9, 11.5, 9.4, and 3.4 μM, respectively. Anticancer agent 63 induce apoptosis in MCF-7 cells via down-regulating the expression of Bcl-2 and up-regulating the expression of IL-2 and Caspase-3. Anticancer agent 63 also shows antioxidant activity.

HY-118762

KGP94	Cathepsin	Cancer
KGP94 is a selective inhibitor of cathepsin L with an IC₅₀ of 189 nM. KGP94 inhibits migration and invasion of metastatic carcinoma and shows low cytotoxicity (GI₅₀=26.9 µM) against various human cell lines.

HY-147864

c-Fms-IN-12	c-Fms c-Kit Apoptosis	Cancer
c-Fms-IN-12 (Compound 4g) is an FMS kinase inhibitor. c-Fms-IN-12 can also inhibits c-KIT. c-Fms-IN-12 is a potential broad-spectrum anticancer agent against multiple cancer types. c-Fms-IN-12 induces A549 cell apoptosis.

HY-133136

PROTAC BRD4 Degrader-2
PROTACs Epigenetic Reader Domain Cancer

PROTAC BRD4 Degrader-2 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 14.2 nM against BRD4 BD1.

HY-16138

Ivaltinostat CG-200745	HDAC MDM-2/p53 Apoptosis	Cancer
Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects.

HY-N0704

Agrimol B	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial	Cancer Infection Metabolic Disease
Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27.

HY-16138A

Ivaltinostat formic CG-200745 formic	HDAC MDM-2/p53 Apoptosis	Endocrinology Inflammation/Immunology
Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects.

HY-N0171A

Beta-Sitosterol (purity>98%) β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)	Apoptosis Endogenous Metabolite	Cancer Inflammation/Immunology Cardiovascular Disease
Beta-Sitosterol (purity>98%) is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171B

Beta-Sitosterol (purity>75%) β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)	Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
Beta-Sitosterol (purity>75%) includes 75% β-sitosterol and 10% campesterol. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>75%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171

Beta-Sitosterol (purity>80%) β-Sitosterol (purity>80%); 22,23-Dihydrostigmasterol (purity>80%)	Endogenous Metabolite Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>80%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-117987

CPS-11 N-(Hydroxymethyl)thalidomide	Nuclear Factor of activated T Cells (NFAT) NF-κB Reactive Oxygen Species	Cancer
CPS-11 (N-(Hydroxymethyl)thalidomide) a Thalidomide (HY-14658) analogue, is a potent anti-cancer agent. CPS-11 inhibits NF-κB, activates NFAT, and repress cytokine expression through elevated ROS. CPS-11 exhibits a wider activity spectrum and higher potency against MM (multiple myeloma) cell lines.

HY-131384

8,11,14-Eicosatriynoic acid 8,11,14-Icosatriynoic acid	Biochemical Assay Reagents	Others
8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandins, leukotriene biosynthesis and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenation The enzyme (COX) and 5-lipoxygenase (5-LO) IC50 values were 0.46 μM, 14 μM and 25 μM, respectively. In addition, it inhibits the action of slow-reacting substances of allergic reactions with IC50 values of 10 μM [1,2]. Lipoxygenase is widely found in fungi, plants and animals, and its content is very high. 12-LO is involved in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and various other NSAIDs, making them clinically important [3]. 5-LO is involved in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization. In vitro: As of now, in vitro studies of 8,11,14-eicosatriynoic acid are still under development. In vivo: To date, in vivo studies of 8,11,14-eicosatriynoic acid are in the development stage. References: [1]. Goetz, J., Sprecher, H., Cornwell, D. and Panganamala, R . Inhibition of prostaglandin biosynthesis by triynoic acid. . prostaglandins. 1976;12(2):187-192. [2]. Sun, F., McGuire, J., Morton, D., Pike, J., Sprecher, H. and Kunau, W. Inhibition of platelet arachidonic acid 12-lipoxygenase by acetylenic acid compounds effect. prostaglandins. 1981;21(2):333-343. [3]. Fitzpatrick, F. Cyclooxygenase: regulation and function. Current agent Design. 2004;10(6):577-588.

Cat. No.	Product Name

HY-L124

Anti-Prostate Cancer Compound Library

2033 compounds

Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.

MCE offers a unique collection of 2033 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.

HY-L107

Anti-Cancer Natural Product Library

1408 compounds

With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers.

MCE offers a unique collection of 1408 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.

Cat. No.	Product Name	Type

HY-D1676

Thymolphthalein monophosphate disodium hydrate

Fluorescent Dyes/Probes

Thymolphthalein monophosphate disodium hydrate is a chromogenic substrate for the determination of acid phosphatase and alkaline phosphatase. Thymolphthalein is released during the reaction, increases the pH of the medium for easy detection, produces color and stops hydrolysis. Thymolphthalein monophosphate disodium hydrate can be used for the specific detection of prostatic phosphatase in serum.

Cat. No.	Product Name	Type

HY-135849

Catalase	Enzyme
Catalase is a key enzyme in the metabolism of H₂O₂ and reactive oxygen species (ROS), and its expression and localization is markedly altered in tumors. Free oxygen radical scavenger.

HY-131384

8,11,14-Eicosatriynoic acid

8,11,14-Icosatriynoic acid

Biochemical Assay Reagents

8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandins, leukotriene biosynthesis and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenation The enzyme (COX) and 5-lipoxygenase (5-LO) IC50 values were 0.46 μM, 14 μM and 25 μM, respectively. In addition, it inhibits the action of slow-reacting substances of allergic reactions with IC50 values of 10 μM [1,2]. Lipoxygenase is widely found in fungi, plants and animals, and its content is very high. 12-LO is involved in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and various other NSAIDs, making them clinically important [3]. 5-LO is involved in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization. In vitro: As of now, in vitro studies of 8,11,14-eicosatriynoic acid are still under development. In vivo: To date, in vivo studies of 8,11,14-eicosatriynoic acid are in the development stage. References: [1]. Goetz, J., Sprecher, H., Cornwell, D. and Panganamala, R . Inhibition of prostaglandin biosynthesis by triynoic acid. . prostaglandins. 1976;12(2):187-192. [2]. Sun, F., McGuire, J., Morton, D., Pike, J., Sprecher, H. and Kunau, W. Inhibition of platelet arachidonic acid 12-lipoxygenase by acetylenic acid compounds effect. prostaglandins. 1981;21(2):333-343. [3]. Fitzpatrick, F. Cyclooxygenase: regulation and function. Current agent Design. 2004;10(6):577-588.

Cat. No.	Product Name	Target	Research Area

HY-P4085

AGR
Peptides Cancer

AGR is a peptide. AGR recognizes lymphatic vessels in fully developed prostate tumors but not in the pre-malignant lesions.
HY-P0013

Antide
D-21074; ORF 23541
GnRH Receptor Cancer

Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Cancer Endocrinology
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer.

HY-P3501

Fexapotide NX-1207 free acid	Apoptosis	Cancer
Fexapotide (NX-1207 free acid) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research.

HY-16168A

Degarelix	GnRH Receptor Apoptosis	Cancer Endocrinology
Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix can be used for prostate cancer research.

HY-16168B

Degarelix acetate hydrate	GnRH Receptor Apoptosis	Cancer Endocrinology
Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research.

HY-16498

Tigapotide PCK-3145	Apoptosis	Cancer
Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels.

HY-16375

Ozarelix D-63153	GnRH Receptor Apoptosis	Cancer
Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer.

HY-P0056

Histrelin	GnRH Receptor	Cancer
Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis.

HY-P3229

SN52	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research.

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Cancer Endocrinology
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.

HY-13673A

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.

HY-P1416

Foxy-5	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.

HY-P1416A

Foxy-5 TFA	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.

HY-P2161B

TAK-683 acetate	Kisspeptin Receptor	Cancer
TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.

HY-P2161A

TAK-683 TFA	Kisspeptin Receptor	Cancer
TAK-683 TFA is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 TFA is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 TFA depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.

HY-P2161

TAK-683	Kisspeptin Receptor	Cancer
TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.

HY-P3853

GR 87389	Neurokinin Receptor	Neurological Disease
GR 87389 is a potent NK2 receptor antagonist. GR 87389 antagonized GA 64349-induced smooth muscle strips contractions in a competitive manner in the human detrusor, prostate and prostatic urethra.

HY-13534

Abarelix
R3827; PPI 149
GnRH Receptor Cancer Endocrinology

Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.
HY-P1813

PSA1 (141-150)
Peptides Cancer

PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.

HY-13534A

Abarelix Acetate PPI 149 Acetate; R 3827 Acetate	GnRH Receptor	Cancer Endocrinology
Abarelix Acetate (PPI 149 Acetate; R 3827 Acetate) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer research.

HY-P4089

REA
Peptides Cancer

REA is a peptide. REA recognizes lymphatics of a premalignant stage, but not to the tumor lymphatic vessels.

HY-P2284

AD 01	Peptides	Cancer
AD 01, a 24 amino acid peptide of FKBPL (FK506-binding protein like), possesses potent anti-angiogenic activity. AD 01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner.

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613)	GnRH Receptor	Cancer Endocrinology
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model.

HY-P3668

[D-Lys6]-LH-RH
GnRH Receptor Cancer Endocrinology

[D-Lys6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH acts as a GnRH receptor agonist.

HY-16215

Mipsagargin G-202	Drug-Linker Conjugates for ADC	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research.

Cat. No.	Product Name	Target	Research Area

HY-P99239

Rosopatamab
HJ 591
Inhibitory Antibodies Cancer

Rosopatamab (HJ 591) is a humanised anti-PSMA monoclonal antibody that can be used in cancer research, particularly in prostate cancer.

HY-P99188

Carlumab CNTO 888	CCR	Cancer
Carlumab (CNTO 888) is a humanised anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer.

HY-P99517

Voxalatamab
JNJ-63898081
CD3 Cancer

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research.

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).

HY-P99217

Rilotumumab AMG 102	c-Met/HGFR	Cancer
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.

HY-P99189

Cixutumumab IMC-A12; NSC742460	Inhibitory Antibodies	Cancer
Cixutumumab (IMC-A12) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.

HY-P99554

Topsalysin PRX-302; PRX302; PSA-PAH1	Inhibitory Antibodies	Cancer
Topsalysin (PRX-302; PRX302; PSA-PAH1) is a PSA-activated protoxin, a pore-forming protein (synthetic proaerolysin) fusion protein with human prostate-specific antigen. Topsalysin has tumor suppression effect in mice modle.

Cat. No.	Product Name	Target	Category

HY-P2450

Leucinostatin A Antibiotic P168	Fungal Antibiotic	Natural Products Classification of Application Fields Disease Research Fields Infection Source classification Microorganisms
Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies.

HY-N8850

Angelol G	Others	Coumarins Structural Classification Phenylpropanoids Source classification Plants Leguminosae Campylotropis hirtella (Franch.) Schindl.
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH).

HY-N10491

Spongionellol A	P-glycoprotein	Diterpenoids Source classification Microorganisms
Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer.

HY-N7924

Astragenol	Others	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants other families
Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research.

HY-N10492

Spongionellol A analog 1	P-glycoprotein	Diterpenoids Source classification Microorganisms
Spongionellol A analog 1, an analog of Spongionellol A (HY-10491), is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A analog 1 has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A analog 1 can be used in the research of cancers, such as prostate cancer.

HY-N10265

Stephacidin B	Endogenous Metabolite	Alkaloids Alkaloid Dimers Classification of Application Fields Disease Research Fields Cancer Source classification Microorganisms
Stephacidin B is a fungal metabolite. Stephacidin B shows in vitro cytotoxicity against a panel of human tumor cell lines. Stephacidin B shows the strongest cytotoxicity against testosterone-dependent prostate LNCaP cancer cells.

HY-126412

Neochamaejasmine A	Apoptosis	Biflavones Flavonoids Plants Thymelaeaceae Stellera chamaejasme Linn.
Neochamaejasmine A is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L.. Neochamaejasmine A inhibits proliferation, induces cell cycle arrest and apoptosis in tumor cells. Neochamaejasmine A can be used in the research of cancers such as prostate cancer, hepatoma cancer.

HY-N6601

Pomolic acid Randialic acid A	Apoptosis	Triterpenes Terpenoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Staphyleaceae Euscaphis japonica other families
Randialic acid A (Pomolic acid) is a pentacyclic triterpene isolated from Euscaphis japonica (Tunb.). Randialic acid A (Pomolic acid) inhibits tumor cells growth and induces cell apoptosis. Randialic acid A (Pomolic acid) has a potential for the treatment of prostate cancer (PC).

HY-N2908

Atraric acid Methyl atrarate	Androgen Receptor NO Synthase p38 MAPK NF-κB	Phenols Plants
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases.

HY-N2059

Santalol	Others	Natural Products Classification of Application Fields Disease Research Fields Cancer Source classification Plants Santalaceae Santalum album Linn. other families
Santalol is a mixture of α and β-isomer santalol. α-santalol is isolated from sandalwood oil. α-santalol is a promising anti-cancer agent against cancers such as oral, breast, prostate and skin cancer.

HY-B1150

Clofoctol	Bacterial SARS-CoV Antibiotic	Monophenols Antibiotics Phenols Structural Classification Other Antibiotics Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Clofoctol is a bacteriostatic antibiotic. Clofoctol is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria. Clofoctol is only functional against Gram-positive bacteria and can penetrate into human lung tissue. Clofoctol is also an inhibitor of prostate cancer. Clofoctol has antiviral potency.

HY-N10578

Genkwadaphnin	Others	Terpenoids Structural Classification Diterpenoids Thymelaeaceae Daphne genkwa Sieb. et Zucc. Plants
Genkwadaphnin is a daphnane diterpenoid, targeting of importin-β1 to reduce the nuclear accumulation of key CRPC drivers, and shut down their downstream oncogenic signaling. Genkwadaphnin shows potent anti-tumor activity and inhibits castration-resistant prostate cancer (CRPC) in vivo in mice.

HY-B0371

Terazosin	Adrenergic Receptor	Classification of Application Fields Disease Research Fields Endocrinology
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.

HY-17473

Embelin Embelic acid; Emberine; NSC 91874	IAP NF-κB Apoptosis Autophagy	Quinones Benzene Quinones Classification of Application Fields Disease Research Fields Cancer Source classification Plants Myrsinaceae Embelia laeta (Linn.) Mez
Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC₅₀=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells.

HY-N0551

Wedelolactone	Caspase Lipoxygenase Apoptosis	Structural Classification Phenols Polyphenols Compositae Eclipta prostrata (Linn.) Linn. Plants Inflammation/Immunology Disease Research Fields Classification of Application Fields
Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase (5-Lox) with an IC₅₀ of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer.

HY-N1050

Zederone	mTOR	Sesquiterpenes Structural Classification Terpenoids Source classification Plants Zingiberaceae Curcuma elata Roxb.
Zederone, a germacrane-type sesquiterpene, has potently cytotoxic against human white blood cancer cells and human prostate cancer cells. Zederone significantly inhibits the proliferation and downregulates the protein expressions of mTOR, and phosphorylated p70 S6 kinase (p-p70s6K) in SKOV3 cells.

HY-N0790

Lupeol Clerodol; Monogynol B; Fagarasterol	Androgen Receptor Apoptosis	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Cancer Source classification Plants other families
Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC).

HY-N6969

Dicentrine	Adrenergic Receptor	Isoquinoline Alkaloids Alkaloids Disease Research Fields Classification of Application Fields Endocrinology Source classification Plants Menispermaceae Stephania epigaea Lo
Dicentrine is a natural product isolated from the plant Stephania epigaea Lo with antihypertensive effect. Dicentrine is an α₁-adrenoceptor antagonist which has effective against human hyperplastic prostates.

HY-113289

Brassicasterol	Androgen Receptor HSV Bacterial Drug Metabolite	Steroids Classification of Application Fields Disease Research Fields Cancer Infection Source classification Animals
Brassicasterol, a metabolite of Ergosterol, plays a role in the inhibitory effect on bladder carcinogenesis promotion via androgen signaling. Brassicasterol shows dual anti-infective properties against HSV-1 (IC₅₀=1.2 µM) and Mycobacterium tuberculosis, and cardiovascular protective effect. Brassicasterol exerts an anti-cancer effect by dual-targeting AKT and androgen receptor signaling in prostate cancer.

HY-N0058

4,5-Dicaffeoylquinic acid Isochlorogenic acid C	HBV Endogenous Metabolite Apoptosis Glucosidase	Phenols Polyphenols Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Infection Source classification Plants Compositae Bowdichia virgilioides Endogenous metabolite
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects.

HY-N0288

Lycorine	Fatty Acid Synthase (FASN) Virus Protease Bacterial Apoptosis	Pyrrole Alkaloids Isoquinoline Alkaloids Alkaloids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Amaryllidaceae other families
Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a K_d value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription. Lycorine is also a melanoma vasculogenic inhibitor. Lycorine can be used for the study of prostate cancer and metabolic diseases.

HY-113332

Myristoleic acid	Apoptosis Endogenous Metabolite	Ketones, Aldehydes, Acids Structural Classification Palmae Microorganisms Serenoa repens Plants Animals Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells.

HY-15194

Dimethylcurcumin ASC-J9; GO-Y025	Androgen Receptor	Phenylpropanoids Simple Phenylpropanols Classification of Application Fields Disease Research Fields Cancer Source classification Plants Zingiberaceae Zingiber officinale
Dimethylcurcumin (ASC-J9) is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.

HY-N0610A

Cinnamic acid 3-Phenylacrylic acid; β-Phenylacrylic acid	Endogenous Metabolite	Phenylpropanoids Structural Classification Simple Phenylpropanols Endogenous metabolite Source classification Disease Research Fields Cancer Classification of Application Fields
Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

HY-N3755

Dihydroresveratrol	Estrogen Receptor/ERR	Phenols Polyphenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants Dioscoreaceae Dioscorea bulbifera Linn.
Dihydroresveratrol, a potent phytoestrogen, is a hormone receptor modulator. Dihydroresveratrol exhibits proliferative effects in androgen-independent prostate and breast cancer cells at picomolar and nanomolar concentrations.

HY-13626

Spisulosine ES-285	PKC	Alkaloids Other Alkaloids Marine natural products Animals Source classification Disease Research Fields Cancer Classification of Application Fields
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation.

HY-109564

5α-Pregnane-3β,6α-diol-20-one	Drug Metabolite	Steroids Structural Classification Endogenous metabolite Source classification Disease Research Fields Cancer Classification of Application Fields
5α-Pregnane-3β,6α-diol-20-one is a mitogenic metabolite of progesterone, and it can be produced in starved androgen-responsive prostate cancer cells.

HY-N7045

Isosilybin B	Androgen Receptor Apoptosis	Phenols Flavanonols Polyphenols Flavonoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Compositae Glycine soya Cyamopsis tetragonoloba (L.) Taub.
Isosilybin B, a flavonolignan isolated from Silybum marianum, has anti-prostate cancer (PCA) activity via inhibiting proliferation and inducing G1 phase arrest and apoptosis. Isosilybin B causes androgen receptor (AR) degradation.

HY-N0819

Raddeanin A	Apoptosis	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Cancer Source classification Plants other families
Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway.

HY-N1338

Royleanone NSC 122417	mTOR Akt	Quinones Anthraquinones Structural Classification Labiatae Cyanthillium cinereum (L.) H. Rob. Plants Source classification
Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits mTOR/PI3/AKT signaling pathway in LNCaP prostate cancer cells.

HY-N7043

Isosilybin A	Apoptosis	Flavonoids Flavanonols Phenols Polyphenols Classification of Application Fields Disease Research Fields Cancer Source classification Plants Compositae Glycine soya Cyamopsis tetragonoloba (L.) Taub.
Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis.

HY-N2415

Podophyllotoxone	Microtubule/Tubulin	Phenylpropanoids Lignans Classification of Application Fields Disease Research Fields Cancer Source classification Plants Berberidaceae Dysosma versipellis (Hance) M. Cheng ex Ying
Podophyllotoxone is isolated from the roots of Dysosma versipellis and has anti-cancer activities.Podophyllotoxone is able to inhibit the tubulin polymerization.

HY-110028

Leelamine hydrochloride	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor	Terpenoids Structural Classification Diterpenoids Pinus massoniana Lamb. Pinaceae other families Plants Source classification Disease Research Fields Classification of Application Fields Endocrinology
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees. Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis^[2,3].

HY-110066

(Z)-Guggulsterone	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR	Steroids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Burseraceae Commiphora myrrha (Nees) Engl.
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis. (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection.

HY-N0103A

Sophocarpine monohydrate	Autophagy Apoptosis PI3K Akt Influenza Virus	Alkaloids Piperidine Alkaloids Classification of Application Fields Disease Research Fields Infection Inflammation/Immunology Source classification Plants Leguminosae Sophora japonica L.
Sophocarpine (monohydrate) is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine (monohydrate) significantly inhibits the growth of gastric cancer (GC) cells through multiple mechanisms such as induction of autophagy, activation of cell apoptosis and down-regulation of cell survival PI3K/AKT signaling pathway. Sophocarpine (monohydrate) has been demonstrated to have anti-tumor activity in various cancer cells, including hepatocellular carcinoma, prostate cancer and colorectal cancer.

HY-N0103

Sophocarpine	Autophagy Apoptosis PI3K Akt Influenza Virus	Alkaloids Piperidine Alkaloids Inflammation/Immunology Infection Disease Research Fields Classification of Application Fields Source classification Plants Leguminosae Sophora flavescens
Sophocarpine is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory. Sophocarpine significantly inhibits the growth of gastric cancer (GC) cells through multiple mechanisms such as induction of autophagy, activation of cell apoptosis and down-regulation of cell survival PI3K/AKT signaling pathway. Sophocarpine has been demonstrated to have anti-tumor activity in various cancer cells, including hepatocellular carcinoma, prostate cancer and colorectal cancer.

HY-17503

Metoprolol	Adrenergic Receptor Apoptosis	Classification of Application Fields Disease Research Fields Endocrinology
Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties.

HY-15371

Forskolin Coleonol; Colforsin; HL 362	Adenylate Cyclase FXR Autophagy	Terpenoids Structural Classification Diterpenoids Gochnatia polymorpha (Less) Cabr. Labiatae Plants Source classification Inflammation/Immunology Metabolic Disease Disease Research Fields Classification of Application Fields Endocrinology
Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC₅₀ of 41 nM and an EC₅₀ of 0.5 μM for type I adenylyl cyclase. Forskolin is also an inducer of intracellular cAMP formation. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy.

HY-N0704

Agrimol B	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial	Structural Classification Phenols Polyphenols Rosaceae Plants Agrimonia pilosa Ledeb. Metabolic Disease Disease Research Fields Classification of Application Fields
Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27.

HY-N0171A

Beta-Sitosterol (purity>98%) β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)	Apoptosis Endogenous Metabolite	Steroids Structural Classification Leguminosae Plants Source classification Glycine max (L.) merr Inflammation/Immunology Disease Research Fields Classification of Application Fields Cardiovascular Disease
Beta-Sitosterol (purity>98%) is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171B

Beta-Sitosterol (purity>75%) β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)	Apoptosis	Steroids Classification of Application Fields Disease Research Fields Cardiovascular Disease Inflammation/Immunology Source classification Plants other families
Beta-Sitosterol (purity>75%) includes 75% β-sitosterol and 10% campesterol. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>75%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171

Beta-Sitosterol (purity>80%) β-Sitosterol (purity>80%); 22,23-Dihydrostigmasterol (purity>80%)	Endogenous Metabolite Apoptosis	Steroids Classification of Application Fields Disease Research Fields Cardiovascular Disease Inflammation/Immunology Source classification Plants other families Endogenous metabolite
Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>80%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

Species:	Human (12) Mouse (1) Rat (1)
Tag:	His (10) Tag Free (1) GST (2) Fc (1) B2M (1)
Source:	HEK293 (7) P. pastoris (1) E. coli (6)

Cat. No.	Product Name	Species	Source

HY-P71775

PSCA Protein, Mouse (P.pastoris, His)
Psca; prostate stem cell antigen
Mouse P. pastoris

HY-P79138

PSP94/MSMB Protein, Human (His) Beta-microseminoprotein; MSMB; Immunoglobulin-binding factor; IGBF; PN44; prostate secreted seminal plasma protein; prostate secretory protein of 94 amino acids; PSP-94; PSP94; Seminal plasma beta-inhibin; PRSP; prostate Secretory Protein of 94 Amino Acid	Human	E. coli

HY-P75896

JTB Protein, Human (HEK293, Fc)
Jumping translocation breakpoint protein; prostate androgen-regulated protein; JTB; HSPC222
Human HEK293
HY-P73730

PARM-1 Protein, Human (HEK293, His)
prostate androgen-regulated mucin-like protein 1; PARM-1
Human HEK293
HY-P70606

Kallikrein-3/PSA Protein, Human (237a.a, HEK293, His)
prostate-specific antigen; PSA; Gamma-seminoprotein; Kallikrein-3; P-30 antigen; Semenogelase; KLK3; APS
Human HEK293
HY-P76943

Galectin-8 Protein, Rat (GST)
Galectin-8; Gal-8; Po66 Carbohydrate-Binding Protein; Po66-CBP; prostate Carcinoma Tumor Antigen 1; PCTA-1; LGALS8
Rat E. coli
HY-P70190

Galectin-8/LGALS8 Protein, Human
rHuGalectin-8; Galectin-8; Gal-8; Po66 Carbohydrate-Binding Protein; Po66-CBP; prostate Carcinoma Tumor Antigen 1; PCTA-1; LGALS8
Human E. coli

HY-P70266

Kallikrein-3/PSA Protein, Human (244a.a, HEK293, His) rHuprostate-specific antigen/KLK3, His; prostate-Specific Antigen; PSA; Gamma-Seminoprotein; Seminin; Kallikrein-3; P-30 Antigen; Semenogelase; KLK3; APS	Human	HEK293

HY-P700081AF

Animal-Free Galectin-8/LGALS8 Protein, Human (His)
Galectin-8; Galectin-8; Gal-8; Po66 Carbohydrate-Binding Protein; Po66-CBP; prostate Carcinoma Tumor Antigen 1; PCTA-1; LGALS8
Human E. coli

HY-P70266A

Kallikrein-3/PSA Protein, Human (244a.a, HEK293, C-His) rHuprostate-specific antigen/KLK3, His; prostate-Specific Antigen; PSA; Gamma-Seminoprotein; Seminin; Kallikrein-3; P-30 Antigen; Semenogelase; KLK3; APS	Human	HEK293

HY-P700382

Galectin-8/LGALS8 Protein, Human (GST) LGALS8; lectin, galactoside-binding, soluble, 8; galectin-8; galectin 8; PCTA 1; galectin-8g; Po66 carbohydrate binding protein; po66 carbohydrate-binding protein; prostate carcinoma tumor antigen 1; Gal-8; PCTA1; PCTA-1; Po66-CBP	Human	E. coli

HY-P72146

Claudin-3/CLDN3 Protein, Human (His-B2M) C7orf1; Claudin-3; Claudin3; CLD3_HUMAN; CLDN 3; Cldn3; Clostridium perfringens enterotoxin receptor 2; CPE R2; CPE receptor 2; CPE-R 2; CPE-receptor 2; CPETR 2; CPETR2; HRVP 1; HRVP1; Rat ventral prostate 1 like protein; Rat ventral prostate.1 protein homolog; RVP1; Ventral prostate.1 like protein; Ventral prostate.1 protein homolog	Human	E. coli

HY-P700472

Claudin-3/CLDN3 Protein-VLP, Human (HEK293, His) C7orf1; Claudin-3; Claudin3; CLD3_HUMAN; CLDN 3; Cldn3; Clostridium perfringens enterotoxin receptor 2; CPE R2; CPE receptor 2; CPE-R 2; CPE-receptor 2; CPETR 2; CPETR2; HRVP 1; HRVP1; Rat ventral prostate 1 like protein; Rat ventral prostate.1 protein homolog; RVP1; Ventral prostate.1 like protein; Ventral prostate.1 protein homolog	Human	HEK293
Claudin-3/CLDN3 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays.

HY-P7895

Clusterin/APOJ Protein, Human (427a.a, HEK293, His) rHuClusterin/APOJ, His ; Clusterin; Aging-Associated Gene 4 Protein; Apolipoprotein J; Apo-J; Complement Cytolysis Inhibitor; CLI; Complement-Associated Protein SP-40; Ku70-Binding Protein 1; NA1/NA2; Testosterone-Repressed prostate Message 2; TRPM-2; CLU; APOJ; CLI; KUB1	Human	HEK293
Clusterin/APOJ Protein, Human (HEK 293, His) expresses in HEK 293 cells with a His tag at the N-terminus. Clusterin (CLU) is a multifunctional glycoprotein that has been implicated in several physiological and pathological states, including Alzheimer’s disease (AD).

Cat. No.	Product Name

HY-70002S1

Enzalutamide-d6

Enzalutamide-d₆ is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1].

HY-70002S

Deutenzalutamide
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.

HY-B0192S

Alfuzosin-d7
Alfuzosin-d₇ is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].

HY-B0192AS1

Alfuzosin-d7 hydrochloride
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-14249S

Bicalutamide-d4
Bicalutamide-d₄ is the deuterium labeled Bicalutamide. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer[1].

HY-13702S

Nilutamide-d6
Nilutamide-d₆ (Nilandron-d6) is the deuterium labeled Nilutamide. Nilutamide (Nilandron) is a non-steroidal anti-androgen agent proposed in the research of metastatic prostatic carcinoma[1][2].

HY-N0610AS

Cinnamic acid-d6
Cinnamic acid-d₆ is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

HY-13626S

Spisulosine-d3
Spisulosine-d₃ is deuterium labeled Spisulosine. Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKC

HY-B0661AS1

Tamsulosin-d4 hydrochloride
Tamsulosin-d₄ (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-B0661AS

Tamsulosin-d5 hydrochloride
Tamsulosin-d₅ (hydrochloride) is the deuterium labeled Tamsulosin hydrochloride. Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-N0610AS2

Cinnamic acid-13C3
Cinnamic acid-¹³C₃ (3-Phenylacrylic acid-¹³C₃) is the ¹³C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

HY-B0371S

Terazosin-d8
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

HY-111614S

Melengestrol acetate-d6

Melengestrol acetate-d₆ is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity[1]. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research[2].

HY-111614S2

Melengestrol acetate-d3

Melengestrol acetate-d₃ is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity[1]. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research[2].

HY-111614S1

Melengestrol acetate-d2

Melengestrol acetate-d₂ is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity[1]. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research[2].

HY-B0391S1

Naftopidil-d5
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

HY-13635S

Finasteride-d9

Finasteride-d₉ is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].

HY-135794S

11-Ketodihydrotestosterone-d3

11-Ketodihydrotestosterone-d₃ is the deuterium labeled 11-Ketodihydrotestosterone. 11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a Ki of 20.4 nM and an EC50 of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells[1][2].

HY-16474S

Relugolix-d6

Relugolix-d₆ is deuterium labeled Relugolix. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209)[1]. Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al[2].

prostate

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products